

 **NorthShore**
University HealthSystem

Kellogg Cancer Center



Shaping the future
of cancer care

2021 ANNUAL REPORT

Our 2021 Annual Report showcases highlights of our clinical and research initiatives. To learn more about our full range of programs and services, please visit northshore.org/cancer.

Shaping the Future of Cancer Care

As we celebrate the 40th anniversary of the NorthShore University HealthSystem (NorthShore) Kellogg Cancer Center in 2021, we reflect on our founding as an innovative, state-of-the-art community cancer center. While much has changed in terms of technology and sophisticated diagnosis and treatment options, our mission to provide patient-focused care has remained steadfast.



Dr. Bruce Brockstein



Dr. David J. Winchester

Our multidisciplinary teams of physicians, nurses and other specially trained clinicians come together with a shared goal of providing the best possible personalized care to each individual and improving outcomes for cancer patients.

We continue to push the limits of innovation with the latest treatments in immunotherapy and targeted therapy based on tumor genomics, building on the strengths of our nationally recognized molecular pathology and diagnostics laboratory.

NorthShore's Kellogg Cancer Genomics Initiative is growing, as is our team of physician experts providing advanced surgical and clinical care. As we expand our successful model of care serving a growing numbers of patients, we remain dedicated to offering the most progressive and compassionate care.

We are excited about expanding our multidisciplinary services to Swedish Hospital and look forward to developing our clinical and community partnerships with Northwest Community Hospital.

Our academic affiliation with the University of Chicago Pritzker School of Medicine not only helps train the next generation of physician leaders, but also allows our patients to continue to benefit from our shared clinical and research initiatives and collective expertise.

NorthShore is certified by the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) as a premier medical provider for practicing the highest standards of quality cancer care.

We are beyond grateful to the many patients and families who support our efforts with charitable donations. These contributions are crucial, particularly in funding research initiatives and many patient support activities. We offer our sincere thanks to our donors, whose gifts make a real difference in patient outcomes and quality of life.

This report offers a look at some of the highlights of the past year. We thank you for your interest in our shared mission to set new standards of care for cancer patients.

A handwritten signature in black ink, appearing to be 'B. Brockstein'.

Bruce Brockstein, MD
Medical Director, NorthShore Kellogg
Cancer Center
Head, Division of Hematology/Oncology
Kellogg-Scanlon Chair of Oncology

A handwritten signature in black ink, appearing to be 'D. Winchester'.

David J. Winchester, MD
Chairman, NorthShore Cancer Committee
Associate Director for Surgical Specialties
NorthShore Kellogg Cancer Center
Board of Directors
David P. Winchester, MD, Chair of Surgical Oncology



Leveraging the Benefits of Immunotherapy


Immunotherapy continues to drive major advances in treating cancer, and our team remains ahead of the curve in offering pioneering therapies and developing a robust immunotherapy program. By harnessing the body's own immune system to identify and eradicate cancer cells, immunotherapy is showing benefits for a growing majority of cancers while tumor genomic testing expands that reach beyond a cancer's site of origin.

New advancements and better immunotherapy medications are in development giving hope to more and more patients.

Nearly a third of Kellogg Cancer Center patients are treated with immunotherapy medications. Major institutional investments in personalized medicine have enhanced our immunotherapy capabilities: capital purchases and expansion in the NorthShore laboratory, launching the Kellogg Cancer Genomics Initiative (KCGI), and support of bioinformatics, to name a few.

While the COVID-19 pandemic slowed progress on hiring a new immunotherapy program director, Kellogg Cancer Center Medical Director Bruce Brockstein, MD, and Head of Lung Cancer and Director of Quality Tom Hensing, MD, MS, continue to lead this effort with renewed momentum.

Immunotherapy Total Number of Patients and Doses



Studying COVID-19 Antibody Response in Cancer Patients

Knowledge about COVID-19 and vaccine response in cancer patients is scant, and a team of NorthShore physician-scientists led by Janardan D. Khandekar, MBBS, MD, is leading a study to learn more. "Sequential Measurement of Immunologic Memory of Cancer Patients Following mRNA based Vaccine Administration" has enrolled more than 100 patients with breast, GI, lung and gynecologic malignancies. Participants are divided into two

groups—the first of which is on chemotherapy and the second who may be on hormonal therapy or observation only.

Data collected will help provide information related to cancer patients' need for and benefits of boosters. Oncologists Bruce Brockstein, MD, Teresa Law, MD, Tom Hensing, MD, MS, and Robert Marsh, MD are co-investigators.

Patient response and participation has been enthusiastic.



Advanced Practice Nurse Annette Sereika is a key member of the NorthShore Center for Personalized Medicine team and plays a major role in the Kellogg Cancer Genomics Initiative.

KCGI: Cutting Edge Analysis of Tumor Tissue

The Kellogg Cancer Genomics Initiative (KCGI) uses next-generation tumor sequencing to characterize the tumor mutations for an initial group of 500 Kellogg Cancer Center patients with advanced or metastatic cancers where tumor genetics may help determine the best course of therapy. Testing identifies DNA alterations as well as genetic translocations and includes pharmacogenomics studies (genetic testing to determine an individual's ability to metabolize medication and therefore susceptibilities to side effects and effectiveness of medications). The genomic data is used to both refine diagnoses and identify precise molecular targets for specific treatment.

While the study was initially delayed during the pandemic, patients are now being enrolled and the feedback has been tremendous. "Our patients are very engaged and wanting to participate, and it's been gratifying and humbling to see how passionate they are about wanting to help people in the future," said Advanced Practice Nurse in NorthShore's Center for Personalized Medicine Annette Sereika.

A unique program, the KCGI features a broad, multidisciplinary team and leverages NorthShore's outstanding bioinformatics and lab capabilities running cutting-edge testing in house.

Immunotherapy, Compassionate Care Provides Healing and Hope

Todd Neihoff was just 37 years old when he was first diagnosed with Stage III colon cancer in 2017. Disappointed with the care he was receiving near his home in the Peoria area, Neihoff's wife Shawna made it her mission to find better options.

"They were basically telling us there was nothing else they could do, and I wasn't willing to give up," said Shawna Neihoff, whose online research led her to NorthShore Kellogg Cancer Center and a team of physicians who have provided advanced treatment and a new lease on life for the Neihoffs.

The aggressive cancer spread to Todd Neihoff's pancreas, necessitating surgery with Melissa Hogg, MD, an expert in complex oncologic surgery. Neihoff also saw oncologist Janardan D. Khandekar, MBBS, MD, as part of NorthShore's Center for Personalized Medicine, where they learned he carried a genetic mutation that was particularly responsive to immunotherapy.

Groundbreaking immunotherapy treatments under the direction of oncologist Ariel Polish, MD, have now helped control

Todd Neihoff's cancer while significantly improving his quality of life. "The genomic analysis with Dr. Khandekar and the Personalized Medicine team really transformed his trajectory," said Dr. Polish.

The Neihoffs drive three hours each way to reach NorthShore Evanston Hospital every three weeks for his treatment, but they are beyond grateful to have found treatment without the debilitating side effects of chemotherapy and a team of clinicians focused on his care.

"I used to have a backpack that I carried around with all his test results—but when we came to Kellogg for care, it was like a breath of fresh air and I could breathe again," said Shawna Neihoff. "I don't have to carry that backpack around, I know I can check all his test results on NorthShoreConnect, and I know that Dr. Polish and the whole team actually care about him."

Todd Neihoff was amazed by how quickly he started feeling better with immunotherapy and had the energy to live life again. "Within the first couple treatments, it just took off. I feel good now. I can get up every day and hang out with my grandkids and do the things I want to do," he said.

Palliative care specialist Lauren Wiebe, MD, has also been a key player on Neihoff's clinical team helping control his pain. "Dr. Wiebe is amazing. He is as close to 100% pain-free as he could be," said Shawna Neihoff. "We are so thankful for everyone at the Kellogg Cancer Center. I know I wouldn't have my husband today if it wasn't for them."



Dr. Ariel Polish (left) and Dr. Lauren Wiebe have given cancer patient Todd Neihoff a new lease on life.

NIH Funds Support Pioneering Research

Coveted funds from National Institutes of Health (NIH) were awarded in support of NorthShore's research into immunotherapy response on triple-negative breast cancer. Prem Seth, PhD, who served as the Director of the Gene Therapy Program before his untimely death in August 2021, initiated the study and was critical in securing the prestigious Research Project Grant (RO1).

The study aims to assess the effect of specific "viral oncolytics" on augmenting immune checkpoint inhibitors to generate an improved immune response to tumors that do not traditionally send signals to the immune system that something is wrong. These "cold" tumors have not been as responsive to immunotherapy as "hot" tumors in other parts of the body, including the lungs.

Lung cancer has been one of the most responsive to immunotherapy, while breast cancer has been slow to respond. The development of novel therapeutics for the treatment of metastatic breast and other cancers is a major unmet need this research aims to address. Dr. Seth's longtime colleague Weidong Xu, PhD, will now lead this promising research at NorthShore.

In Memoriam Dr. Prem Seth

A pioneer and a role model, Dr. Prem Seth served as the Gene Therapy Program Director at NorthShore and held important leadership positions at Northwestern University and the University of Chicago. Dr. Seth led a dedicated team of scientists working to develop breakthrough treatments for cancer.

His work was supported by the NIH and the American Cancer Society. He was a well-recognized international authority on gene therapy for cancer. In addition to many other roles, Dr. Seth served on the editorial board of several prestigious academic journals, including *Cancer Gene Therapy* and *Human Gene Therapy*.

Dr. Seth pioneered the use of adenovirus-mediated gene targeting in developing new cancer therapy. In recent years, he developed novel oncolytic viruses that can selectively kill breast cancer cells and be used in conjunction with immunotherapies.

"Prem's contributions to NorthShore and the larger medical community will make a difference for countless cancer patients," said Bruce Brockstein, MD, Kellogg Cancer Center Medical Director. "We will miss his compassion, curiosity and genuine desire to improve the lives of others."



Research to Transform Breast Cancer Care

Katharine Yao, MD, Vice Chair for Research and Development, Department of Surgery, is leading several innovative research studies aimed at actively preventing breast cancer and improving outcomes and quality of life for patients.

Novel Mindfulness Study

Anxiety and fear often follow a breast cancer diagnosis and can overwhelm some women to the point where it makes it difficult to understand their treatment plan. Dr. Yao's mindfulness study will evaluate how to help patients best move forward and tackle their new journey. Short, educational mindfulness video modules tailored to the newly diagnosed breast cancer patient will address overcoming and coping with cancer and will be accessible online. Dr. Yao and her team will study the impact of the mindfulness videos on overall stress and anxiety, and will collect blood samples to examine stress biomarkers. David Victorson, PhD, Associate Professor of Medical Social Sciences at Northwestern University, is a key partner in this study. This study is supported in part by a grant from the John Wayne Cancer Foundation.

Improving Risk Assessment

Developing a proven, data-backed risk assessment score to help women determine their individual breast cancer risk is an important strategy to help prevent breast cancer.

The lack of a consistent way for primary care physicians and patients to evaluate risk has led Dr. Yao to develop a new initiative to improve risk assessments—"Personalized Risk Assessment at NorthShore" (the PRANS Study). Currently, most women are screened the same way for breast cancer, but we know that some women need different screening modalities than other women. In an effort to move toward personalized breast

screening, Dr. Yao and others are developing a comprehensive risk assessment mechanism specifically integrated in the NorthShore's electronic health record (EHR) system. This risk assessment mechanism will generate a risk score for every woman coming in for a screening mammogram and will help identify those at higher risk who may need more than just a mammogram for screening. NorthShore has one of the largest screening mammography programs in the region, conducting more than 80,000 mammograms annually. We also have a robust EHR system, Epic, that is used by a majority of other academic health systems across the country. These enhancements make the breast centers at NorthShore an ideal environment to create best practice for personalized breast cancer screening.

A Phase I pilot study of this project will use NorthShore screening sites to collect risk factors and validate the risk model in Epic. As the study progresses, Dr. Yao's team will also measure how the risk score impacts anxiety, attitudes toward screening, risk perception and decisional satisfaction.

Studying Universal Genetic Testing for Breast Cancer Patients

While it is standard of care to offer genetic testing to newly diagnosed breast cancer patients who meet set criteria, new evidence is emerging that these guidelines may miss a gene mutation in a significant number of women. The American Society of Breast Surgeons issued new guidelines stating all newly diagnosed breast cancer patients should undergo genetic testing regardless of family history. However, many breast surgeons are not comfortable with ordering genetic testing, and it is not clear whether all patients will have access to universal genetic testing. Dr. Yao is working closely with Catherine Pesce, MD, to collect physician opinions on universal genetic testing for newly diagnosed breast cancer patients. This study is supported by a NorthShore Breast and Ovarian Cancer Research Pilot Award. Dr. Pesce and Dr. Yao will use these findings to inform national guidelines and to develop educational materials to help surgeons learn how to order genetic testing.



Dr. Katharine Yao leads innovative research aimed at advancing breast cancer prevention and treatment.

Studying COVID-19 Antibody Response in Cancer Patients

Knowledge about COVID-19 and vaccine response in cancer patients is scant, and a team of NorthShore physician-scientists led by Janardan D. Khandekar, MBBS, MD, is leading a study to learn more. "Sequential Measurement of Immunologic Memory of Cancer Patients Following mRNA-Based Vaccine Administration" has enrolled more than 100 patients with breast, gastrointestinal, lung and gynecologic malignancies. Participants are divided into two groups—the first of which are receiving chemotherapy and

the second who may be treated with hormonal therapy or observation only. Data collected will help provide information related to cancer patients' response to treatment and susceptibility to COVID-19 and to gain insight into the potential benefit of adjunctive treatments such as monoclonal antibodies or antiviral medications. Oncologists Bruce Brockstein, MD, Teresa Law, MD, Thomas Hensing, MD, MS, and Robert Marsh, MD, are co-investigators. Patient response and participation have been enthusiastic.

Early Detection Key to Treating Lung Cancer

A family history of heart disease led George Vollkommer to carefully monitor his health, including undergoing cardiac scans to check the condition of his heart. While Vollkommer’s heart was in fact in good condition, the scan showed a small nodule on his lung.

As lung nodules are fairly common, his physician suggested he do another scan in a few months just to be safe. The nodule grew quickly and Vollkommer was referred to thoracic surgeon Seth Krantz, MD. Following a more detailed PET scan, Dr. Krantz suggested surgery to remove the suspicious growth, which turned out to be very early stage lung cancer.

A 67-year-old never smoker, Vollkommer considered himself very lucky to have his cancer detected so early and removed with virtually no chance of recurrence. “It was small, but aggressive. I trusted Dr. Krantz.



Dr. Seth Krantz helps lead NorthShore’s efforts to promote lung cancer screening to discover the disease at early and more treatable stages.

“I’ve been going to NorthShore forever and I felt better after talking with him,” he said. “They took it out, no chemo—boom, I was done.”

Dr. Krantz performed a small surgical biopsy of the lung, and on-site pathology confirmed in real time that it was cancer, prompting him to do a lobectomy, removing a small section of the right lung. The minimally invasive surgery is performed robotically with 3D cameras, and all lymph nodes in the area are also checked to assess whether patients are essentially cancer-free.

“The surgery went well, and the nurses and everyone at Evanston Hospital were great,” said Vollkommer, who recovered quickly and returned to a regular exercise program. “I’m all for preventive medicine. I want to make sure I’m around for my wife and family.”

Wanting to do everything possible to ensure that his cancer would not return, Vollkommer had his home tested for radon, which is a leading cause of lung cancer in nonsmokers, and found that it was five times above acceptable levels. He has since had his home remediated and continues to monitor the radon levels on a daily basis.

“I wish we could find more early lung cancer through screenings,” said Dr. Krantz, who is hopeful this will be the case as NorthShore’s lung cancer screening program continues to grow. A Kellogg Cancer Center nurse navigator currently works with primary care physicians to help refer appropriate patients for screenings. She then works with those patients who are diagnosed with lung cancer.

Two large, randomized, controlled trials have shown that low-dose CT screening for those at risk of lung cancer is very successful at diagnosing early-stage cancer when it is most treatable, and NorthShore has been an early adopter encouraging those who are eligible to get screened.

Eligibility requirements for lung cancer screening include: 50–80 years old; a “20 pack-year” history of smoking history, meaning one pack a day for 20 years or two packs a day for 10 years; and a current smoker or has quit within the last 15 years. Patients are advised to check with their insurance plan to ensure screening coverage.

Helping Patients Quit Smoking

Research has shown that a combination of medication and behavioral therapy can be the best way to help a smoker successfully kick the habit. And often the timing for successful quitting is linked to an acute incident, like a cancer diagnosis.

The Kellogg Cancer Center team is working to help more smokers quit, offering all new cancer patients a referral to an appointment with one of our five specially trained, certified tobacco treatment specialists.


The smoking cessation program at Kellogg Cancer Center began about 10 years ago with one certified specialist. It has continued to grow exponentially with a larger team seeing more and more patients each year, in both new and follow-up sessions.

There is compelling evidence that continued tobacco use after a cancer diagnosis decreases survival, reduces treatment efficacy, increases/prolongs treatment toxicity and increases the risk of recurrence.

“Our goal is to get them in for a consult as soon as they’re diagnosed,” said thoracic surgeon Seth Krantz, MD. He reminds patients

that it is never too late to quit and that it often takes multiple attempts to quit smoking for good.

Tobacco Cessation Program Participation



Oral Chemotherapy Monitoring Improves Patient Experience

As more and more patients are receiving oral chemotherapy—treatment that can be taken at home versus traditional chemotherapy administered through an IV—Kellogg Cancer Center pharmacists have been ahead of the curve in monitoring patient adherence.

For patients, there are obviously big benefits in terms of convenience and flexibility. But there are challenges for the clinical team that no longer has eyes on patients during treatment. Side effect management can also be an issue as patients may not be spending regular time at the Kellogg Cancer Center where there is ample opportunity to talk with nurses, pharmacists, physicians etc.

“If they don’t call us, we don’t know what kind of side effects they may be having,” said oncology pharmacist Shannon Hartman, PharmD. “It puts a lot of responsibility on the patient.”

Kellogg Cancer Center’s specially trained oncology pharmacists started a pilot program in 2014 for patients on a commonly prescribed breast cancer

drug that often resulted in side effects, calling patients on a regular schedule to check in, monitor their experience, answer questions and offer support.

Thanks to philanthropic support, there is now a half-time oncology pharmacist dedicated to the oral chemotherapy monitoring program. Oncology pharmacist Diane Chon, PharmD, has expanded the program to now cover patients on approximately 20 different chemotherapy medications. The monitoring has been built into the Epic electronic health record (EHR) system so all healthcare providers can access the information.

As soon as one of the prescriptions is sent, an oncology pharmacist reviews the order to ensure there is no potential drug interactions with any of the patient’s other medications. A pharmacist also reaches out to the patient for an initial phone consult to answer questions and explain the critical importance of adhering to the medication schedule. The patient is called on a monthly basis—or more often if needed to assess for side

effects—to see if there is a need for a dose adjustment or a visit with the Kellogg Cancer Center clinical team. Oral chemotherapy patients also are given a direct line to call with questions.

The oral chemotherapy program is a multidisciplinary effort. The oncology collaborative nurses complete a pre-assessment of patients prior to starting any oral chemotherapy. They also do one-to-one patient teaching to ensure patients are aware of side effects and resources that are available. The nurses also help monitor patients’ adherence with their treatment plan, which is all recorded in their EHR.

“We’re very excited to have this in place and are continuing to increase the number of medications added to the monitoring program,” said Hartman. “We believe that adherence has significantly improved since we started the monitoring program.”

Data around patient satisfaction and interventions is collected and will continue to be tracked as the program grows.

New Recruits Expand Expertise

As the Kellogg Cancer Center continues to serve a growing number of patients and treat the full range of complex conditions, we continue to expand our faculty of talented physicians. New recruits in

the last year have added depth and expertise to our collaborative, multidisciplinary teams. Here are some of our new recruits currently caring for patients:



Saad Arain, MD
Hematology



Carolina Soto Chervin, MD, PhD
Gastroenterology and lung cancers



Amy Wang, MD
Hematology



Hassan Arshad, MD
Head and neck surgeon



Mason Hedberg, MD
Gastrointestinal surgeon



Katherine Wailen Su, MD
Thoracic surgeon

Understanding the Microbiome and Immunotherapy

Carolina Soto Chervin, MD, PhD, brings a unique interest in immunotherapy and how it relates to the body’s microbiome or gut health. A graduate of the MD/PhD Medical Scholars Program (Cancer Immunotherapies) at the University of Illinois, Dr. Soto Chervin also completed her residency and

a fellowship in hematology/oncology at UChicago Medicine.

Gut health is attracting plenty of attention lately, and Dr. Soto Chervin is researching the intersection between gut microbiome, cancer and immunotherapy. Current research is showing that this new arena holds tremen-

dous healing potential from counteracting gastrointestinal side effects of cancer treatment to targeted pre- and probiotics and diet changes, to enhancing treatment response through bacterial or fecal transplants. Dr. Soto Chervin brings particular enthusiasm and aptitude in bridging research and cancer care.

Honoring a Visionary

A true pioneer, Janardan D. Khandekar, MBBS, MD, has helped establish NorthShore as a recognized leader in the field of personalized medicine. His compassion and expertise have brought innumerable benefits to cancer patients for more than four decades.

Dr. Khandekar was the founding Head of the Division of Medical Oncology and drove early innovation and expansion of the Kellogg Cancer Center. As Director of Innovation and Education at the Mark R. Neaman Center for Personalized Medicine, he continues to be a driving force for education and research that will set new standards and improve outcomes in cancer care today and for future generations.

He is a mentor to countless physicians through the American Society of Clinical Oncology and has authored or co-authored 116 peer-reviewed papers and more than 60 other publications.

The exploration of new and novel ideas has been a hallmark of Dr. Khandekar's career, and the Neaman Center for Personalized Medicine expands his legacy of innovation. Using patients' unique DNA to tailor clinical care, identifying new molecular markers on tumors as targets for treatments, and using pharmacogenomics to select the best drug therapy based on a patient's genes are among the advances benefiting NorthShore patients.

The Janardan D. Khandekar, MD, Personalized Medicine Innovation Fund will provide crucial support to spark further innovation in patient care, research and education, expanding the boundaries of knowledge at NorthShore and beyond. If you are interested in learning more or making a gift to honor Dr. Khandekar, please contact Janet Myers, Senior Director of Principal Giving at **(224) 364-7212** or **jmyers3@northshore.org**.



Dr. Janardan Khandekar has a rich legacy of caring for cancer patients and advancing innovations in treatment at NorthShore and beyond.

Integrative Oncology Scholars



Oncology Nurse Practitioners Sara Reynolds (left) and Maggie Keller are part of the final class of talented Integrative Oncology Scholars Program at the University of Michigan.

Funded by the National Cancer Institute, the University of Michigan Integrative Oncology Scholars Program trains a multidisciplinary group of cancer clinicians to integrate evidence-based complementary therapies into conventional care settings.

Kellogg Cancer Center Oncology Nurse Practitioners Maggie Keller and Sara Reynolds are among the talented group of scholars in the current course who are working jointly through

the year-long curriculum with the goal of expanding integrative services for Kellogg Cancer Center patients. The Integrative Oncology Scholars Program is in its fifth and final year.

"NorthShore is fortunate to have a well-established integrative medicine program. We're working closely with the IM team to make these services more available to our Kellogg patients," said Reynolds.

"We believe that increased access to on-site integrative oncology services will benefit our patients," said Keller. "We have really high hopes for the program and have already benefited from discussions with participants from around the country."

Kellogg Cancer Center patients can take advantage of a range of integrative medicine services including acupuncture and traditional chinese medicine, and bodywork that can help offset side effects, increase energy and relaxation, and add to the healing process. Led by Medical Director Leslie Mendoza Temple, MD, the Integrative Medicine Program at NorthShore cares for a significant and growing number of cancer patients. Dr. Mendoza Temple has also completed the Integrative Oncology Scholars Program.

Keller and Reynolds hope to share their knowledge of evidence-based practices with other clinicians at Kellogg Cancer Center, broadening awareness among physicians and other important team members.

"The goal of our integrative oncology capstone is the creation of a business plan for the development of an onsite integrative oncology clinic within the Kellogg Cancer Center," added Reynolds. "We aim to provide integrative oncology consultations and patient-centered, comprehensive, evidence-based integrative support for cancer patients and survivors to improve symptom management and ultimately quality of life."

Dr. Winchester Honored by American College of Surgeons



Dr. David P. Winchester was honored for his vision and dedication to the highest standard of care for breast cancer patients.

Longtime Kellogg Cancer Center surgeon David P. Winchester, MD, FACS, FACR, Emeritus, received the Distinguished Service Award from the American College of Surgeons (ACS)—its highest honor. Dr. Winchester retired after a lengthy career that included leadership roles at NorthShore and academic leadership positions at Northwestern University Feinberg School of Medicine.

The award recognizes Dr. Winchester's vision and dedication in developing a national accreditation program related to the alignment of the highest standards and quality of care in the treatment of breast cancer and rectal cancer. In July 2009, NorthShore's Breast Health Program was the first in the Chicagoland area to be granted accreditation from the National Accreditation Program for Breast Centers.

The ACS Board of Regents Honors Committee selected Dr. Winchester for this distinction "in appreciation for his exceptional and continuous service as a Fellow of the American College of Surgeons and his role as Medical Director for the College's Commission on Cancer (CoC), the American Joint Committee on Cancer (AJCC), the National Cancer Database (NCDB), and the ACS Cancer Research Program (CRP)," according to the award citation.

Dr. Winchester is considered a natural leader who possesses integrity, vision, and a steadfast commitment to the College's initiatives and principles. He serves as a role model to surgeons everywhere "to always do the right thing for patients," the citation notes.

Diagnostic Expertise and Lifesaving Care

Deshanna Louis went from thinking she had a bad case of acid reflux to being diagnosed with COVID-19 and then hospitalized for a very rare condition that nearly killed her in a matter of weeks.

What at first looked like lymphoma was ultimately diagnosed as hemophagocytic lymphohistiocytosis, or HLH, an exceptionally rare and aggressive inflammatory condition that can occur in people with serious infections. Louis credits her diagnosis, and ultimately her survival, to NorthShore oncologist Alla Gimelfarb, MD.

Louis had significant blood count abnormalities, tumors across her abdomen, liver failure and a host of other complications as her system was ravaged by HLH. She underwent four different biopsies, each one coming back negative despite scans that all looked like cancer, explained Dr. Gimelfarb. The condition is so rare that most physicians will see at most one or two cases in their career. NorthShore hematologists are highly attuned to the unique diagnostic criteria for this condition and were able to make the diagnosis here in a timely fashion.

"It is a very complicated diagnosis as it can look like a million other things that all need to be ruled out," said Dr. Gimelfarb. Treatment for HLH is chemotherapy and high-dose steroids, which fortunately put Louis on the path to full recovery despite some pretty rough side effects.

The tumors shrank and the chemotherapy also decreased the catastrophic inflammatory response, explained Dr. Gimelfarb.

"It was scary. We knew I was very sick. There were times I couldn't walk or eat anything," recalled the mother of four. "But I knew Dr. Gimelfarb did absolutely everything she could for me. I never felt lost or like I was just a number to her. She explained everything to me and never left me in the dark."

Dr. Gimelfarb's expertise, coupled with a very collaborative and multi-disciplinary team at Kellogg Cancer Center literally saved Louis' life. "She started responding immediately to the treatment,



Dr. Alla Gimelfarb's excellent diagnostic skills helped save patient Deshanna Louis from a rare and life-threatening condition.

and we knew we were on the right track," said Dr. Gimelfarb. "It was a slow recovery. She was very, very sick, but she was a trooper and she powered through it."

"Just like all our cancer patients, she got incredible care at Kellogg," said Dr. Gimelfarb. "Our nurses are incredible, and the whole team came together for her."

"I feel like I would have died if I had been somewhere else, and I do think Dr. Gimelfarb is a rock star," said Louis. "I'm very thankful."

Nurse Navigators Collaborate for Optimal Patient Experience

Nurse navigators play a critical role for newly diagnosed cancer patients, helping them navigate their new realm and serving as an important source of support and information throughout their journey. As NorthShore begins to integrate oncology services with its newest partners, collaboration between nurse navigators at Kellogg Cancer Center, Northwest Community Hospital and Swedish Hospital has helped streamline processes and identify ways to improve patient experiences.

“Our goal is to achieve standard and efficient transitions throughout NorthShore oncology sites, which will ensure an excellent patient experience,” said Kellogg Cancer Center Director Linda Green. “At our global navigator meetings, everyone is happy to share expertise, resources and problem-solving with their colleagues to ensure seamless connections.”

For lower-volume clinical programs, it’s an easier referral now from one site to another for medical oncologists, radiation oncologists or surgeons, and the collaboration is also beneficial in helping patients looking for second opinions. As navigators are now connected, it eases handoffs when patients transfer from one NorthShore hospital to another for oncology care.



Nurse navigator Brenda O'Brien is part of a collaborative team of NorthShore clinicians dedicated to best practices.

“We’re all learning from each other and trying to implement best practices together,” said Rhea Trbojevic Executive Director of Cancer Services at Northwest Community Hospital.

Educational resources and support groups are also shared across the system, offering patients a broader range of vital support services.

Galter LifeCenter Services Support Patients



Acupuncturist Terri Clemens is part of Swedish Hospital’s Integrated Cancer Care Program offered through the Galter LifeCenter.

Swedish Hospital’s Integrated Cancer Care program helps patients overcome the physical and emotional challenges associated with a cancer diagnosis with specific fundamental fitness and other complementary treatments offered through the Galter LifeCenter.

The medical fundamental fitness program offers patients a way to learn about lifestyle changes in an interactive, supportive environment focused on cardiovascular exercise, strength training, nutrition and more. In addition to weekly sessions, patients are offered a two-month membership to the Galter LifeCenter.

“We get such positive feedback on the program,” said oncologist Jeffrey Cilley, MD. “Everyone who does it loves it and wishes they could do more.”

Patients are taught how to create their own workouts and how to set small goals that can make a big difference. They have access to a variety of medical and fitness experts, including personal trainers with specialized oncology experience and training.

Personal trainers help develop individual customized exercise and wellness programs to help fight depression, anxiety, fatigue, pain and injury and promote overall wellness.

“We know that when you exercise, there’s generally less of a sense of fatigue,” said Dr. Cilley. “The program also helps patients feel like they have more of a sense of control as they cope with cancer treatments.”

Integrative therapy including acupuncture and massage, is also offered at the Galter LifeCenter, which is conveniently located close to the cancer center at Swedish Hospital.

Psychosocial Services Support the Cancer Journey

Comprehensive, patient-centered treatment has long been a hallmark of Kellogg Cancer Center's multidisciplinary approach to cancer care. Psychosocial support for patients and their families is focused on navigating complex emotional challenges that arise from diagnosis through treatment and beyond. Psychosocial support is provided by a dedicated and compassionate team of oncology social workers with decades of experience in the field.

Thanks to generous funding from Carole Levy, Kellogg Cancer Center welcomed a new psychologist to the team in 2021. Elizabeth Kacel, PhD, is a clinical health psychologist who brings years of specialized training in patient care, education and research to the Kellogg Cancer Center community. Her family's experience with the compassionate care provided at the Kellogg Cancer Center 15 years ago inspired her to become a psychologist who could give back to the cancer community. As part of the psychosocial support team, Dr. Kacel is helping expand services available to patients.

Dr. Kacel provides comprehensive psychological services for patients and families with cancer at any point along the care continuum from diagnosis through end of life. Initial psychological evaluations are used to develop personalized treatment plans for stress management and coping during the natural ups and downs of the cancer experience. Dr. Kacel works closely with patients, families, social workers and healthcare providers using scientifically supported approaches to optimize wellbeing and cancer survivorship.



Dr. Elizabeth Kacel brings additional expertise to the Kellogg Cancer Center psychosocial team.

"It is truly an honor to come full circle, returning to the community where it all began, to become a part of the outstanding psychosocial team and to work alongside the dedicated healthcare providers at Kellogg Cancer Center," said Dr. Kacel.

Dr. Kacel is a graduate of Northwestern University. She completed her doctoral degree at the University of Florida and her post-doctoral fellowship at the Mayo Clinic in Rochester, Minnesota.

Highlighting Quality and Safety Survivorship Programs

Carol Rosenberg, MD, the founder and director of NorthShore's Myra Rubenstein Weis (MRW) Living in the Future (LIFE) Cancer Survivorship Program, presented at the American College of Surgeons Quality and Safety Conference.

The presentation, Building an Ecosystem of Post-Treatment Care, highlighted NorthShore's model of cancer survivorship care delivery, which combines survivorship care planning and support of survivors with both individualized and group interventions. The national conference showcases methodologies and programs that serve as examples for meeting Commission on Cancer (CoC) standards.

Dr. Rosenberg initiated the MRW LIFE Program—the first of its kind in the Chicago region—in 2006 and has directed its growth and evolution supporting cancer survivors. In the study, more than 1,000

Myra Rubenstein Weis



CANCER SURVIVORSHIP PROGRAM

survivors who participated in the LIFE Program's exemplary individualized survivorship care planning visit were surveyed about post-treatment concerns and a model aimed at targeted and enhanced survivorship services was developed.

Targeted interventions including enhancements to the cornerstone individualized survivorship visit; consultative services including specialty survivorship care services in rehabilitation, nutrition, cardio-oncology, gynecologic/women's sexual health and smoking cessation; and group education aimed at promoting self-management are among LIFE's holistic approaches to survivorship care.

"It was an honor to have NorthShore's program representing quality and safety standards on a national stage," said Dr. Rosenberg.

2021 Clinical Trials

Oncology Trials

Breast Cancer

EA1181 Compass (HER2-pCR): Perioperative THP and postoperative HP In patients who achieve a pathologic complete response

NRG-BR004 A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer, NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer"

A011801 The CompassHER2 trials (COMprehensive use of Pathologic Response ASSESSment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

Gastrointestinal Cancer

NRG-GI004/SW0G-S1610 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

A021502 A Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

UC14-0594 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma

A021703 Randomized, Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

A221805 Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

NRG-GI005 Phase II/III study of Circulating tumor DNA as a predictive Biomarker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA) (NCT #TBD)

Genitourinary Cancer

AFT-19 A Phase III Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

PCCTC c16-168 A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

Johns Hopkins J1557 Overcoming Drug Resistance in Metastatic Castration-Resistant Prostate Cancer with Novel Combination of TGF- β Receptor Inhibitor LY2157299 and Enzalutamide: A Randomized Multi-Site Phase II Study

Genomic Profiling Genomic Profiling and Clinical Outcomes in Metastatic Castrate-Resistant Prostate Cancer

NRG-GU008 A Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE)

EA8183 A Phase III Study of Early Intervention after RADICAL Prostatectomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

UC13-0540 Afatinib (BIBW 2992) in Advanced Refractory Urothelial Cancer

AVE0-TiNivo-2 A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor

S1806 Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Gynecologic Cancer

Pilot Study Pilot study of the impact of early palliative care on quality of life in recurrent ovarian, fallopian tube and primary peritoneal cancer

AGCT1531 A Phase III Study of Active Surveillance for Low-Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard-Risk Pediatric and Adult Patients with Germ Cell Tumors

GOG-3026 A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum NRG-GY020: Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NCT# 04214067)

NRG-GY020 Randomized Phase III Trial of Radiation

+/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NCT# 04214067)

NRG-GY018 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

NRG-GY014 A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCK)

NRG-GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

NRG-GY022 Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin

GOG 3059/Aravive ABV500-OC-004 A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Head and Neck Cancers

HCN Tissue bank tissue/body fluid procurement and clinical data collection for patients with malignancies of the head and neck area and/or premalignant changes

Merck 3475-689 A Phase III Randomized, Open-Label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable, Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

EA3163 Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Postoperative Radiation Versus Surgery and Postoperative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma

NRG HN005 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

RTOG 1216 Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High Risk Squamous Cell Cancer of the Head and Neck

For more information about clinical trials, visit northshore.org/kellogg-cancer-center/clinical-trials

Hematology

Connect® MDS/AML The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

CIBMTR Research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries

A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (ages 18-39) with Newly Diagnosed Precursor B-Cell ALL

A041702 A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

S1925 Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus DeLayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study

EA9181 A Phase III Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive ALL in Adults

Lung Cancer

LungMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

EA5163/S1709 INSIGNA A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy Induction/Maintenance or Post-Progression in Advanced, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

E4512 A Phase III double-blind trial for surgically resected early-stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein

A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

NRG-LU005 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab (MPDL3280A)

Mirati 516-005 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemo-therapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

EA5181 Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

A081801 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO (ACCIO)

AbbVie M14-239 Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-MET Non-Small Cell Lung Cancer

Neuro Oncology

NRG BN003 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

NRG BN007 A Randomized Phase II/III Open-label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor o-6-methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

A071702 A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

A071801 Phase III Trial of Post-surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

NCI-Connect Nivolumab Rare CNS Trial 17-C-0102 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers

Brain-Up/U of C A Phase I Study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter[1]Methylated IDH Wildtype Glioblastoma

Sarcoma

A091902 A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma

Ayala AL-DES-01 (Ringside) A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Skin Cancer

EA6141 Randomized Phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

Regeneron Cemiplimab Survivorship Epidemiology (CASE) Study

Castle Biosciences Development and Validation of Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Ultimovacs UV1-202 A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma

Other

EAY131 Molecular Analysis for Therapy Choice (MATCH)

EAY131-A A Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

EAY131-C1 Crizotinib in Patients with Tumors with MET Amplification

EAY131-C2 Crizotinib in patients with tumors with MET exon 14 deletion

EAY131-E AZD9291 in patients with tumors having EGFR T790M mutations (except non-small cell lung cancer) or rare activating mutations of EGFR

EAY131-H Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer and Colorectal Adenocarcinoma)

EAY131-L Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

EAY131-V Phase II study of sunitinib in patients with tumors with c-kit mutations (excluding GIST, renal cell carcinoma or pancreatic neuroendocrine tumor)

EAY131-Z1C Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification

EAY131-Z1E LOXO-101 in Patients with Tumors with NTRK Fusions

EAY131-Z1G Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result

ASCO Survey on COVID-19 in Oncology (ASCO) Registry

Covid Antibody Trial Sequential Measurement of Immunologic Memory of Cancer Patients Following mRNA-Based Vaccine Administration

Carevive Opt-In Real World Treatment Experience of Patients with Breast, Lung, Multiple Myeloma, Acute Myelogenous Leukemia or Ovarian Cancer Using Remote Symptom Monitoring

A151804 Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Genomic Panels Prospective Analysis of the Utility of Routine Incorporation of Genomic Panels into the Care of Patients with Metastatic Cancer

continued >

Surgical Oncology Trials

Breast Surgery

EH20-166 The Ergonomic Effects of the Robotic Nipple-Sparing Mastectomy on the Operating Surgeon

EH20-165 Exploring Breast Surgical Oncologist's Attitudes and Comfort Level with Universal Genetic Testing

EH15-297 A randomized Phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy—Alliance A011202

EH20-167 Breast Cancer Stem Cells and Peritumoral Adipose Tissue

EH21-214 The Impact of Breast Cancer Surgical Delays Brought on by the Initial COVID-19 Pandemic Surge on Final Pathologic Tumor Stage

EH17-072 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS

EH17-209 Genetic Determinants of Cooperative Interactions on Breast Cancer Intratumor Heterogeneity

EH18-243 Tell Me Where It Hurts: The Ergonomic Effects of Mastectomies on the Operating Surgeon

EH10-081-ACOSOG Z1071 A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T0-4, N1-2, MO) at Initial Diagnosis

EH20-301 WhySurg for Men: A Male Breast Cancer Survey for Men with Breast Cancer

EH20-303 The WhySurg Study for Men with Breast Cancer: The Physician Perspective

EH19-074 A Prospective, Multicenter Investigation of the da Vinci Xi Surgical System in Nipple-Sparing Mastectomy (NSM) Procedures

EH20-134 The PREPARE Study: Supporting Women with Breast Cancer to Prepare for Treatment

Colorectal Surgery

EH12-468 N1048 A Phase II/III trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision

Head and Neck Surgery

EH17-116 Lipid Tissue from Head and Neck Cancer

Pancreatic Cancer

EH18-265 A Phase III Multicenter, Open-Label, Randomized, Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreaticoduodenectomy

EH08-197T Clinical pancreatic cancer database

EH13-433 Comprehensive Assessments for Clinical Care and Surgical Management Among Individuals with Pancreatic Pathology

EH02-186 The Pancreatic Sample Repository

EH17-132 Assessment of Tumor and Treatment Factors as Predictors of Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma Undergoing Pancreaticoduodenectomy, and Efficacy of Pharmacologic Prophylaxis

EH21-215 Extended Post-Operative Thromboprophylaxis After Pancreatic Resection for Pancreatic Cancer is Associated with Decreased Risk of Venous Thromboembolism in the Minimally Invasive Approach

EH21-099 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Lung and Esophageal Cancer

EH98-136 Establishment and maintenance of a comprehensive thoracic tumor data registry and biorepository

EH18-162 Inherited Cancer Panel Performance in Predicting Outcomes Among Patients Diagnosed with Lung Cancer

EH16-356 Clinical Characteristics of Anti-PD-1/PD-L1 relapses in Non-Small Cell Lung Cancer (NSCLC)

EH16-079 Retrospective chart review study to look at adequacy of lymph node staging in patients undergoing curative anatomic resection for non-small cell lung cancer

EH16-362 Natural History of Indeterminate Lung Nodules

EH20-111 Non Small Cell Lung Cancer Tissue Sample Study

Thyroid Surgery

EH14-058 The establishment of a multidisciplinary comprehensive database of patients for thyroid nodular disease

Genitourinary Cancer

EH09-043 A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

EH13-250 Cancer susceptibility: The ICPCG study (International Consortium for Prostate Cancer Genetics)

EH13-446 A retrospective review of patients who have been removed from study EH09-043: A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

EH14-361 SPORE Project 1: Impact of Germline Genetic Variants and Failure of Active Surveillance for Prostate Cancer

EH14-133 The Lived Experience of Men with Sexual Dysfunction After Prostate Cancer Treatment

EH15-124 Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education (REASSURE ME)

EH16-202 Detecting copy number alterations (CNAs) of MYC and PTEN in biopsy samples to predict clinical outcomes in prostate cancer

EH16-239 The impact of using genetic risk scores (GRSs) for inherited risk assessment of prostate cancer

EH16-183 Evaluation of the utility of the prostate health index in routine clinical practice

EH15-365 Assessing the Clinical Utility of Genetic Risk Scores for Targeted Cancer Screening

EH18-381 A Randomized Phase 3, Open-label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer

EH20-278 A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer

EH20-318 A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy

EH14-206 Nanocytology to mitigate overdiagnosis of prostate cancer

EH16-232 Trends in upper tract urothelial treatment

EH16-240 Timing of artificial urinary sphincter placement

EH16-387 Risk-Stratification of Prostate Cancers via Field Carcinogenesis Nanocytology

For more information about clinical trials, visit northshore.org/kellogg-cancer-center/clinical-trials

2021 Research Publications

- Asbun HJ, Moekotte AL, Vissers FL, Kunzler F, Cipriani F, Alseidi A ... **Talamonti MS**, ... International Study Group on Minimally Invasive Pancreas Surgery (I-MIPS). The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. *Ann Surg.* 2020 Jan;271(1):1-14. doi: 10.1097/SLA.0000000000003590. PMID: 31567509 Review.
- Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N ... **Hulick PJ**, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genet Med.* 2020 Oct;22(10):1653-1666. doi: 10.1038/s41431-020-0862-x. Epub 2020 Jul 15. PMID: 32665703
- Black MH, Li S, LaDuca H, Lo MT, Chen J, Hoiness R, Gutierrez S, Tippin-Davis B, Lu HM, Gielzak M, Wiley K, **Shi Z, Wei J, Zheng SL, Helfand BT**, Isaacs W, **Xu J**. Validation of a prostate cancer polygenic risk score. *Prostate.* 2020 Nov;80(15):1314-1321. doi: 10.1002/pros.24058. Epub 2020 Aug 17. PMID: 33258481
- Bleicher RJ, Moran MS, Ruth K, Edge SB, Dietz JM, Wilke LG, Stearns V, Kurtzman SH, Klein J, **Yao KA**. The Impact of Radiotherapy Delay in Breast Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures. *Ann Surg Oncol.* 2021 Jul 29. doi: 10.1245/s10434-021-10512-1. Online ahead of print. PMID: 34324114
- Bleicher RJ, Moran MS, Ruth K, Edge SB, Dietz JM, Wilke LG, Stearns V, Kurtzman SH, Klein J, **Yao KA**. ASO Visual Abstract: The Impact of Radiotherapy Delay in Breast-Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures. *Ann Surg Oncol.* 2021 Aug 3. doi: 10.1245/s10434-021-10535-8. Online ahead of print. PMID: 34346019
- Bortz MD, Khokar A, Winchester DJ, Moo-Young TA, Ecanow DB, Ecanow JS, Prinz RA**. Radioactive iodine-125 seed localization as an aid in reoperative neck surgery. *Am J Surg.* 2021 Mar;221(3):534-537. doi: 10.1016/j.amjsurg.2020.12.048. Epub 2021 Jan 11. PMID: 33546853
- Bortz MD, Kuchta K, Winchester DJ, Prinz RA, Moo-Young TA**. Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer. *Surgery.* 2021 Jan;169(1):2-6. doi: 10.1016/j.surg.2020.04.003. Epub 2020 Jul 16. PMID: 32682508
- Broyles JM, Liao EC, Kim J, Heistein J, **Sisco M**, Karp N, Lau FH, Chun YS. Acellular Dermal Matrix-Associated Complications in Implant-Based Breast Reconstruction: A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Two Human Tissues. *Plast Reconstr Surg.* 2021 Apr 20. doi: 10.1097/PRS.0000000000008194. Online ahead of print. PMID: 33877063
- Bryan DS, Ferguson MK, Antonoff MB, Backhus LM, Birdas TJ, Blackmon SH, Boffa DJ, Chang AC, Chmielewski GW, Cooke DT, Donington JS, Gaissert HA, Hagen JA, Hofstetter WL, Kent MS, Kim KW, **Krantz SB**, et al. Consensus for Thoracoscopic Left Upper Lobectomy-Essential Components and Targets for Simulation. *Ann Thorac Surg.* 2021 Aug;112(2):436-442. doi: 10.1016/j.athoracsur.2020.06.152. Epub 2020 Oct 27. PMID: 33127408
- Callahan ZM, Liu W, Hou J, Zheng SL, Rehman J, Hedberg HM, Brown CS, Su B, Attaar M, Kuchta K, Regner M, Carbray J, Xu J, Ujiki M**. Somatic DNA copy number alterations in non-dysplastic Barrett's esophagus. *Surg Endosc.* 2021 Jul;35(7):3961-3970. doi: 10.1007/s00464-020-07859-z. Epub 2020 Aug 4. PMID: 32749611
- Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A ... **Xu J**, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nat Genet.* 2021 Jan;53(1):65-75. doi: 10.1038/s41588-020-00748-0. Epub 2021 Jan 4. PMID: 33398198
- Cordova R, Kiekens K, Burrell S, Drake W, Kmeid Z, Rice P, Rocha A, Diaz S, Yamada S, Yozwiak M, Nelson OL, **Rodriguez GC**, Heusinkveld J, Shih IM, Alberts DS, Barton JK. Sub-millimeter endoscope demonstrates feasibility of in vivo reflectance imaging, fluorescence imaging, and cell collection in the fallopian tubes. *J Biomed Opt.* 2021 Jul;26(7):076001. doi: 10.1117/1.JBO.26.7.076001. PMID: 34216135
- Cortina CS, Woodfin AA, Tangalakis LL, Wang X, Son JD, Poirier J, Rao R, **Kopkash K, Madrigano A**. Treating Positive Axillary Disease in Elderly Breast Cancer Patients: The Impact of Age on Radiation Therapy. *Breast Care (Basel).* 2021 Jun;16(3):276-282. doi: 10.1159/000508243. Epub 2020 Jul 13. PMID: 34248469
- Deliere A, Attai D, Victorson D, Kuchta K, Pesce C, Kopkash K, Sisco M, Seth A, Yao K**. Patients Undergoing Bilateral Mastectomy and Breast-Conserving Surgery Have the Lowest Levels of Regret: The WhySurg Study. *Ann Surg Oncol.* 2021 Aug 25. doi: 10.1245/s10434-021-10452-w. Online ahead of print. PMID: 34432189
- Dietz JR, Moran MS, Isakoff SJ, Kurtzman SH, Willey SC, Burstein HJ, ... **Yao KA**. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium. *Breast Cancer Res Treat.* 2020 Jun;181(3):487-497. doi: 10.1007/s10549-020-05644-z. Epub 2020 Apr 24. PMID: 32333293
- Ellis RJ, Zhang LM, Ko CY, Cohen ME, Bentrem DJ, Bilimoria KY, Yang AD, **Talamonti MS**, Merkow RP. Variation in Hospital Utilization of Minimally Invasive Distal Pancreatectomy for Localized Pancreatic Neoplasms. *J Gastrointest Surg.* 2020 Dec;24(12):2780-2788. doi: 10.1007/s11605-019-04414-7. Epub 2019 Nov 25. PMID: 31768832
- Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA ... **Hulick PJ**, et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nat Genet.* 2020 Jan;52(1):56-73. doi: 10.1038/s41588-019-0537-1. Epub 2020 Jan 7. PMID: 31911677
- Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL ... **Hulick PJ**, et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genet Epidemiol.* 2020 Jul;44(5):442-468. doi: 10.1002/gepi.22288. Epub 2020 Mar 1. PMID: 32115800
- Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators (**Shevrin D**). Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. *NEJM J Med.* 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. PMID: 32905676 Clinical Trial.
- Frankenstein Z, Basanta D, Franco OE, Gao Y, Javier RA, Strand DW, Lee M, **Hayward SW**, Ayala G, Anderson ARA. Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression. *Nat Ecol Evol.* 2020 Jun;4(6):870-884. doi: 10.1038/s41559-020-1157-y. Epub 2020 May 11. PMID: 32393869
- Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, ... **Helfand BT**, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *J Clin Oncol.* 2020 Aug 20;38(24):2798-2811. doi: 10.1200/JCO.20.00046. Epub 2020 Jun 9. PMID: 32516092
- Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, ... **Helfand BT**, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, **Xu J**, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *J Clin Oncol.* 2020 Aug 20;38(24):2798-2811. doi: 10.1200/JCO.20.00046. Epub 2020 Jun 9. PMID: 32516092
- Gremore TM, **Brockstein B**, Porter LS, **Brenner S, Benfield T**, Baucom DH, **Sher TG**, Atkins D. Couple-based communication intervention for head and neck cancer: a randomized pilot trial. *Support Care Cancer.* 2021 Jun;29(6):3267-3275. doi: 10.1007/s00520-020-05848-5. Epub 2020 Oct 26. PMID: 33106976 Clinical Trial
- Hayward SW**. Immunotherapeutic Response in Tumors Is Affected by Microenvironmental ROS. *Cancer Res.* 2020 May 1;80(9):1799-1800. doi: 10.1158/0008-5472.CCR-20-0590. PMID: 32366527
- Helseth DL Jr, Gulukota K, Miller N, Yang M, Werth T, Sabatini LM, Bouma M, Dunnenberger HM, Wake DT, Hulick PJ, Kaul KL, Khandekar JD**. Flype: Software for enabling personalized medicine. *Am J Med Genet C Semin Med Genet.* 2021 Mar;187(1):37-47. doi: 10.1002/ajmg.c.31867. Epub 2020 Dec 3. PMID: 33270363 Free PMC article.
- Hepburn AC, Curry EL, Moad M, Steele RE, **Franco OE**, Wilson L, Singh P, Buskin A, **Crawford SE**, Gaughan L, Mills IG, **Hayward SW**, Robson CN, Heer R. Propagation of human prostate tissue from induced pluripotent stem cells. *Stem Cells Transl Med.* 2020 Jul;9(7):734-745. doi: 10.1002/sctm.19-0286. Epub 2020 Mar 14. PMID: 32170918
- Holoubek SA, MacKinney EC, Khokar AM, Kuchta KM, Winchester DJ, Prinz RA, Moo-Young TA**. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm. *Surgery.* 2021 Aug 10; S0039-6060(21)00571-7. doi: 10.1016/j.surg.2021.05.054. Online ahead of print. PMID: 34384604

continued >

Holoubek SA, Yan H, Khokar AH, Kuchta KM, Winchester DJ, Prinz RA, Moo-Young TA. Aggressive variants of papillary thyroid microcarcinoma are associated with high-risk features, but not decreased survival. *Surgery*. 2020 Jan;167(1):19-27. doi: 10.1016/j.surg.2019.03.030. Epub 2019 Oct 16. PMID: 31627846

Holoubek SA, Yan H, Kuchta KM, Winchester DJ, Moo-Young TA, Prinz RA. Trends in nonoperative management of papillary thyroid microcarcinoma. *J Surg Oncol*. 2020 May;121(6):952-957. doi: 10.1002/jso.25845. Epub 2020 Mar 18. PMID: 32189361

Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, **Marsh R**, Kozloff MF, Polite BN, Kindler HL, Sharma MR. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. *Clin Cancer Res*. 2020 Jan 1;26(1):18-24. doi:10.1158/1078-0432.CCR-19-1483. Epub 2019 Sep 26. PMID: 31558477

Kakarla M, ChallaSivaKanaka S, **Hayward SW, Franco OE.** Race as a Contributor to Stromal Modulation of Tumor Progression. *Cancers (Basel)*. 2021 May 28;13(11):2656. doi: 10.3390/cancers13112656. PMID: 34071280

Kantor O, Chang C, **Yao K**, Boughey J, Roland C, Francescatti AB, Blair S, Dickson Witmer D, Hunt KK, Nelson H, Weiss A, Oseni T. Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers. *Ann Surg Oncol*. 2021 Sep;28(9):4995-5004. doi: 10.1245/s10434-020-09533-z. Epub 2021 Jan 9. PMID: 33423122

Kaul K, et al. Cell-free nucleic acids in cancer: Current approaches, challenges, and future directions" Chapter 14, *Advances in Molecular Pathology*, Elsevier, in press.

Khandekar M and **Khandekar J.** Messenger RNA (mRNA) – A forgotten molecule; its past, present, and future for therapeutics. *Clin Microbiol Infect Dis*. 2021 June 30; 6: 1-4. doi: 10.15761/CMID.1000190. Review Article.

Khokar AM, Holoubek SA, Kuchta KM, Winchester DJ, Prinz RA, Moo-Young TA. Survival with Follicular and Hurthle Cell Microcarcinoma Compared to Papillary Thyroid Microcarcinoma: A Population Study of 84,532 Patients. *World J Surg*. 2020 Feb;44(2):469-478. doi: 10.1007/s00268-019-05264-9. PMID: 31863140

Khokar AM, Kuchta KM, Moo-Young TA, Winchester DJ, Prinz RA. Increasing trend of bilateral neck exploration in primary hyperparathyroidism. *Am J Surg*. 2020 Mar;219(3):466-470. doi: 10.1016/j.am surg.2019.09.039. Epub 2019 Oct 3. PMID: 31630823

Khokar AM, Kuchta KM, Moo-Young TA, Winchester DJ, Prinz RA. Parathyroidectomy is Safe in Elderly Patients: A National Surgical Quality Improvement Program Study. *World J Surg*. 2020 Feb;44(2):526-536. doi: 10.1007/s00268-019-05280-9. PMID: 31722077

Kopkash K, Novak K, Murphy R, Deliere A, Kuchta K, Rabbitt S, Pesce C, Winchester D, Yao K. Improving the Breast Surgeon's Ergonomic Workload for Nipple-Sparing Mastectomies Using Exercise and Operating Room Positioning Protocol. *Ann Surg Oncol*. 2021 Jul 27. doi: 10.1245/s10434-021-10447-7. Online ahead of print. PMID: 34318384

Kopkash K, Sisco M, Poli E, Seth A, Pesce C. The modern approach to the nipple-sparing mastectomy. *J Surg Oncol*. 2020 Jul;122(1):29-35. doi: 10.1002/jso.25909. Epub 2020 Mar 26. PMID: 32219847 Review.

Kopkash K. ASO Author Reflections: How Do We Improve Ergonomics for the Breast Surgeon During Nipple-Sparing Mastectomies? *Ann Surg Oncol*. 2021 Aug 12. doi: 10.1245/s10434-021-10606-w. Online ahead of print. PMID: 34383192

Lemke AA, Amendola LM, Kuchta K, Dunnenberger HM, Thompson J, Johnson C, Ilbawi N, Oshman L, Hulick PJ. Primary Care Physician Experiences with Integrated Population-Scale Genetic Testing: A Mixed-Methods Assessment. *J Pers Med*. 2020 Oct 13;10(4):165. doi: 10.3390/jpm10040165. PMID: 33066060

Lin M, Bakhsheshian J, Strickland B, Rennert RC, Chen JW, Van Gompel JJ, Young RL 2nd, Kumar PP, Coppens J, Curry WT, Zacharia BE, **Bailes JE**, Zada G. Navigable Channel-Based Trans-Sulcal Resection of Third Ventricular Colloid Cysts: A Multicenter Retrospective Case Series and Review of the Literature. *World Neurosurg*. 2020 Jan;133:e702-e710. doi: 10.1016/j.wneu.2019.09.134. Epub 2019 Sep 28. PMID: 31574336

Liu L, Deng J, Cibull T, **Pesce CE.** "Invasive breast cancer found in a patient with new onset pemphigus foliaceus". *Journal of The American Academy of Dermatology Case Reports*. 2021. [In Press]

Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, **Rodriguez GC**, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. *Gynecol Oncol*. 2020 Jan;156(1):131-139. doi: 10.1016/j.ygyno.2019.10.026. Epub 2019 Nov 21. PMID: 31759774

Mato A, Nabhan C, Lamanna N, Kay NE, **Grinblatt DL**, Flowers CR, Farber CM, Davids MS, Swern AS, Sullivan K, Flick ED, Gressett Ussey SM, Gharibo M, Kiselev P, Sharman JP. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. *Blood Adv*. 2020 Apr 14;4(7):1407-1418. doi: 10.1182/bloodadvances.2019001145. PMID: 32271900

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, **Tafur A**, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. *J Thromb Haemost*. 2020 Feb;18(2):411-421. doi: 10.1111/jth.14662. Epub 2019 Nov 28. PMID: 31630479 Clinical Trial.

Molins L, Lanuti M, Force S, Woolley S, **Krantz S**, Creedon EE, Schwiens ML, Singleton DW, Waggoner JR, Fryrear R 2nd, Licht P. Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracic Surgery Lobectomy. *J Surg Res*. 2020 Sep; 253:26-33. doi: 10.1016/j.jss.2020.03.023. Epub 2020 Apr 19. PMID: 32320894

Morales A, Greenberg M, Nardi F, Gil V, Hayward SW, Crawford SE, Franco OE. Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells. *Lab Invest*. 2021 Jul;101(7):921-934. doi: 10.1038/s41374-021-00583-9. Epub 2021 Apr 6. PMID: 33824421

Ngamruengphong S, Ferri L, Aihara H, Draganov PV, Yang DJ, Perbtani YB, ... **Ujiki MB**, et al. Efficacy of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasia in a Large Cohort in North America. *Clin Gastroenterol Hepatol*. 2021 Aug;19(8):1611-1619.e1. doi: 10.1016/j.cgh.2020.06.023. Epub 2020 Jun 18. PMID: 32565290

Olson DJ, Eroglu Z, **Brockstein B**, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. *J Clin Oncol*. 2021 Aug 20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. Epub 2021 May 4. PMID: 33945288

Paintal AS, Brockstein BE. PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma. *Head Neck Pathol*. 2020 Sep;14(3):657-665. doi: 10.1007/s12105-019-01097-z. Epub 2019 Nov 13. PMID: 31721075

Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, **Grinblatt DL**, et al. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. *Int J Lab Hematol*. 2021 Jun;43(3):426-432. doi: 10.1111/ijlh.13400. Epub 2020 Nov 21. PMID: 33220019

Patel VL, Busch EL, Friebe TM, Cronin A, Leslie G, McGuffog L, Adlard J ... **Hulick PJ**, et al. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. *Cancer Res*. 2020 Feb 1;80(3):624-638. doi: 10.1158/0008-5472.CAN-19-1840. Epub 2019 Nov 13. PMID: 31723001

Pesce C, Jaffe J, Kuchta K, Yao K, Sisco M. Patient-reported outcomes among women with unilateral breast cancer undergoing breast conservation versus single or double mastectomy. *Breast Cancer Res Treat*. 2021 Jan;185(2):359-369. doi: 10.1007/s10549-020-05964-0. Epub 2020 Oct 8. PMID: 33033966

Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, Jackson M, Dolinsky JS, LaDuca H, Xu J, Black MH, **Helfand BT.** Diagnosing hereditary cancer predisposition in men with prostate cancer. *Genet Med*. 2020 Sep;22(9):1517-1523. doi: 10.1038/s41436-020-0830-5. Epub 2020 May 22. PMID: 32439974

- Riaz IB, Fuentes HE, Ahmed Naqvi SA, He H, Riaz Sipra QU, **Tafur AJ**, Padranos L, Wysokinski WE, Marshall AL, Vandvik PO, Montori V, Bryce AH, Liu H, Badgett RG, Murad MH, McBane RD 2nd. TEMPORARY REMOVAL: Direct Oral Anticoagulants Compared with Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. *Mayo Clin Proc*. 2021 Jun 22; S0025-6196(20)31373-2. doi: 10.1016/j.mayocp.2020.10.041. Online ahead of print. PMID: 34172290
- Schaid DJ, McDonnell SK, FitzGerald LM, DeRycke L, Fogarty Z, Giles GG, ... **Helfand B**, et al. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. *Eur Urol*. 2021 Mar;79(3):353-361. doi: 10.1016/j.eururo.2020.07.038. Epub 2020 Aug 14. PMID: 32800727
- Schaid DJ, McDonnell SK, FitzGerald LM, DeRycke L, Fogarty Z, Giles GG, ... **Xu J**, Isaacs W, Ostrander EA, Thibodeau SN. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. *Eur Urol*. 2021 Mar;79(3):353-361. doi: 10.1016/j.eururo.2020.07.038. Epub 2020 Aug 14. PMID: 32800727
- Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators (**Saha P**). Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. PMID: 32101663
- Seth AK**, Cordeiro PC. Stability of long term outcomes in implant-based breast reconstruction: An evaluation of 12-year surgeon- and patient-reported outcomes in 3489 non-radiated and radiated implants. *Plast Reconstr Surg*. 2020;146(3):474-484. doi: 10.1097.PRS.0000000000007117. PMID: 32842095
- Seth AK**, Singhal D. Immediate lymphatic reconstruction for breast cancer. *Ann Breast Surg*. Accepted for publication.
- Shi Z, Wei J, Na R, Resurreccion WK, Zheng SL, Hulick PJ, Helfand BT, Talamonti MS, Xu J**. Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank. *Int J Cancer*. 2021 Apr 1;148(7):1658-1664. doi: 10.1002/ijc.33431. Epub 2020 Dec 18. PMID: 33300603
- Silvestri V, Leslie G, Barnes DR; CIMBA Group, Agnarsson BA, Aittomäki K, Alducci E ... **Hulick PJ**, et al. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncol*. 2020 Aug 1;6(8):1218-1230. doi: 10.1001/jamaoncol.2020.2134. PMID: 32614418
- Sisco M**. The burden of postmastectomy breast reconstruction. *J Surg Oncol*. 2020 Dec;122(7):1298-1299. doi: 10.1002/jso.26213. Epub 2020 Sep 15. PMID: 32935352
- Somasegar S, Hoppenot C, Kuchta K, Sereika A, Khandekar J, Rodriguez G, Moore E, Hurteau J, Jenkins-Vogel T**. Outcomes After Targeted Treatment Based on Somatic Tumor Genetic Testing for Women with Gynecologic Cancers. In press; Available online 9 September 2021. <https://doi.org/10.1016/j.ygyno.2021.08.027>
- Standardizing Care of Neuro-oncology Patients Using a Customized Electronic Medical Record Toolkit. *Mayo Clin Proc Innov Qual Outcomes*. 2021 Jun 5;5(3):625-634. doi: 10.1016/j.mayocp.2021.04.001. eCollection 2021 Jun. PMID: 34195554
- Strohbehn GW, Saint S, **Grinblatt DL**, Moe J, Dhaliwal G. As the Story Unfolds. *J Hosp Med*. 2021 Jul;16(7):428-433. doi: 10.12788/jhm.3518. PMID: 34197309
- Sullivan K, Kaminer LS, Grinblatt DL, Campbell NP, Nocon CC, Harper AJ, Kang JH, Sarav M, Curtis BR, Brockstein BE**. Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies. *JCO Oncol Pract*. 2021 Mar;17(3):153-155. doi: 10.1200/JCO.20.00734. Epub 2020 Dec 3. PMID: 33270522
- Suman P, Razdan SN, Wang CH, Tulchinsky M, Ahmed L, **Prinz RA, Winchester DJ**. Thyroid lobectomy for T1b-T2 papillary thyroid cancer with high-risk features. *JACS* 2020 230(1):136-144.
- Thompson J, **Dunnenberger HM, DePersia A**, Lemke AA, Dilzell-Yu K, Purcell S, Matsil A, Ilbawi N, **Khandekar J**, Revis J, **Hulick PJ**. Clinical outcomes from a genetic family health history screening tool in a primary care network. In progress.
- Thoracic Surgery Outcomes Research Network, Inc, Antonoff M, Backhus L, Boffa DJ, Broderick SR, Brown LM, Carrott P, Clark JM, Cooke D, David E, Facktor M, Farjah F, Grogan E, Isbell J, Jones DR, Kidane B, Kim AW, Keshavjee S, **Krantz S**, et al. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. *J Thorac Cardiovasc Surg*. 2020 Aug;160(2):601-605. doi: 10.1016/j.jtcvs.2020.03.061. Epub 2020 Apr 9. PMID: 32689703
- Vickman RE**, Broman MM, Lanman NA, **Franco OE**, Sudyantni PAG, Ni Y, Ji Y, **Helfand BT, Petkewicz J, Paterakos MC, Crawford SE, Ratliff TL, Hayward SW**. Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. *Prostate*. 2020 Feb;80(2):173-185. doi: 10.1002/pros.23929. Epub 2019 Nov 25. PMID: 31763714
- Vickman RE**, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, Deng WM, Granneman JG, Hildesheim J, Kalluri R, Lau KS, Lengyel E, Lundeberg J, Moscat J, Nelson PS, Pietras K, Politi K, Puré E, Scherz-Shouval R, Sherman MH, Tuveson D, Weeraratna AT, White RM, Wong MH, Woodhouse EC, Zheng Y, **Hayward SW**, Stewart SA. Deconstructing tumor heterogeneity: the stromal perspective. *Oncotarget*. 2020 Oct 6;11(40):3621-3632. doi: 10.18632/oncotarget.27736. eCollection 2020 Oct 6. PMID: 33088423
- Vickman RE, Franco OE**, Moline DC, Vander Griend DJ, Thumbikat P, **Hayward SW**. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. *Asian J Urol*. 2020 Jul;7(3):191-202. doi: 10.1016/j.ajur.2019.10.003. Epub 2019 Oct 19. PMID: 32742923 Review
- Vining CC, Eng OS, **Hogg ME**, Schuitevoerder D, Silverman RS, **Yao KA, Winchester DJ**, Roggin KK, **Talamonti MS**, Posner MC, Turaga KK, Tseng J. Virtual Surgical Fellowship Recruitment During COVID-19 and Its Implications for Resident/Fellow Recruitment in the Future. *Ann Surg Oncol*. 2020 Dec;27(Suppl 3):911-915. doi: 10.1245/s10434-020-08623-2. Epub 2020 May 18. PMID: 32424589
- Vining CC, **Kuchta K**, Berger Y, **Paterakos P**, Schuitevoerder D, Roggin KK, **Talamonti MS, Hogg ME**. Robotic pancreaticoduodenectomy decreases the risk of clinically relevant post-operative pancreatic fistula: a propensity score matched NSQIP analysis. *HPB (Oxford)*. 2021 Mar;23(3):367-378. doi: 10.1016/j.hpb.2020.07.004. Epub 2020 Aug 15. PMID: 32811765
- Vining CC, **Kuchta K**, Schuitevoerder D, **Paterakos P**, Berger Y, Roggin KK, **Talamonti MS, Hogg ME**. Risk factors for complications in patients undergoing pancreaticoduodenectomy: A NSQIP analysis with propensity score matching. *J Surg Oncol*. 2020 Aug;122(2):183-194. doi: 10.1002/jso.25942. Epub 2020 May 23. PMID: 32445612
- Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang E, Saha P, Gulukota K, Helseth DL**, Guise T, Prabhkar BS, **Kaul K**, Schreiber H, **Seth P**. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor-β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. *Hum Gene Ther*. 2020 Aug;31(15-16):863-880. doi: 10.1089/hum.2020.078. Epub 2020 Jun 12. PMID: 32394753
- Yao K**, Bleicher R, Moran M, Chang C, Dietz J, Stearns V, Connolly J, Sarantou T, Kurtzman S; National Accreditation Program for Breast Centers Data Working Group. Differences in physician opinions about controversial issues surrounding contralateral prophylactic mastectomy (CPM): A survey of physicians from accredited breast centers in the United States. *Cancer Med*. 2020 May;9(9):3088-3096. doi: 10.1002/cam4.2914. Epub 2020 Mar 11. PMID: 32159280
- Yao K**, Clifford J, Li S, LaDuca H, Hulick P, Gutierrez S, Black MH. Prevalence of Germline Pathogenic/Likely Pathogenic Variants in Patients with Second Breast Cancers. *JNCI Cancer Spectrum* 2020 (accepted).
- Yao KA**, Attai D, Bleicher R, **Kuchta K**, Moran M, Boughey J, Wilke LG, Dietz JR, Stevens R, **Pesce C, Kopkash K**, Kurtzman S, Sarantou T, Victorson D. Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study). *Breast Cancer Res Treat*. 2021 Apr;186(3):625-635. doi: 10.1007/s10549-021-06101-1. Epub 2021 Jan 31. PMID: 33517522
- Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G ... **Hulick PJ**, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nat Genet*. 2020 Jun;52(6):572-581. doi: 10.1038/s41588-020-0609-2. Epub 2020 May 18. PMID: 32424353
- Zhu Y, Dalrymple SL, Coleman I, **Zheng SL, Xu J**, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. *Oncogene*. 2020 Nov;39(45):6935-6949. doi: 10.1038/s41388-020-01479-6. Epub 2020 Sep 28. PMID: 32989253

2021 Academic Leadership Roles and Awards

Kellogg Cancer Center physicians are active in a broad range of regional and national organizations.

Matthew Adess, MD

Awards:

Chicago Magazine Top Cancer Doctors, 2021

Bruce Brockstein, MD

- Member, Head and Neck Committee, Eastern Cooperative Oncology Group, 2000–present

Editorial:

- UpToDate* (Online Textbook), Chapter Editor, *Head and Neck Cancer*, 2000–present
- Reviewer: *The Oncologist*, *European Journal of Cancer*

Awards:

- Chicago Magazine* Top Doctors 2006, 2008, 2010, 2012, 2014, 2016, 2018, 2019, 2020, 2021
- Chicago Magazine* Top Cancer Doctors 2017, 2019, 2020, 2021

Nicholas Campbell, MD

Editorial:

Reviewer: *Lung Cancer*, *Clinical Case Reports*

Claus Fimmel, MD, CPE

- Advisory Board, American Liver Foundation, Chicago Chapter, 2008–present

Editorial:

Reviewer: *Hepatology*, *American Journal of Gastroenterology*, *American Journal of Physiology*, *Journal of Hepatology*, *Journal of Laboratory and Clinical Investigation*, *Laboratory Investigation*, *American Journal of Pathology*, *Oncogene*, *Gastroenterology*, *Clinical Gastroenterology and Hepatology*, *Journal of Cellular Biochemistry*, *Journal of Proteome Research*, *Proceedings of the National Academy of Sciences*, *PLOS Medicine*, *ACG Case Reports Journal*, *World Journal of Hepatology*

David Grinblatt, MD

- Community Oncology Committee, ALLIANCE for Clinical Trials in Oncology, 2010–present

Editorial:

Ad hoc Reviewer: *Annals in Oncology*, 1996–present

Brian Helfand, MD

- Promotion to Clinical Professor, Pritzker School of Medicine
- NorthShore University, Most Outstanding Academician–2020
- Virtual perspectives in Urology: Point Counterpoint: “All men with prostate cancer and all patients with advanced disease should undergo germline testing.”
- Next generation imaging in prostate cancer; UsToo Prostate Cancer Support Group
- Grand Rounds: Genomic Testing in Prostate Cancer: George Washington University, Invited Speaker
- Organizer and Speaker: Plenary Session, American Urologic Association; Genetics in Urology
- Speaker and Organizer: Philadelphia Cancer Consensus Conference: Prostate Cancer

Thomas Hensing, MD

- Promotion to Clinical Professor, Pritzker School of Medicine
- Respiratory Health Association, Lung Cancer Initiative Advisory Council, 2005–present
- ALLIANCE for Clinical Trials in Oncology, Respiratory Committee Member, 2010–present
- CoC/NCDB Lung Quality Measures Group, 2011–present
- Respiratory Health Association, Invited Member, Scientific Advisory Committee, 2019–present

Awards:

- Chicago Magazine* Top Cancer Doctors, 2021

Melissa Hogg, MD

- SAGES (Society of Gastrointestinal and Endoscopic Surgery Association) Robotics Task Force, Lead of Robotic Biliary Working Group, 2015–present
- SSO (Society of Surgical Oncology) Hepatobiliary Disease Site Work Group, 2015–present; Co-Chair 2018, Chair 2020
- AHPBA (American Hepato-Pancreato-Biliary Association) Training Committee, 2015–2019
- Fellowship Council, HPB working group representing SAGES, 2017–present
- SAGES (Society of Gastrointestinal and Endoscopic Surgery Association) HPB Task Force 2017–present; Co-Chair 2019–present
- AAS Leadership Committee, 2017–2020
- AHPBA Program Committee, 2019–present
- International Minimally Invasive Pancreas Surgery, Founding Member, 2019–present
- AWS Faculty Coach (Female surgical residents at other programs), 2019–present
- AHPBA Executive Board Liaison, 2020–present
- SAGES (Society of Gastrointestinal and Endoscopic Surgery Association) Oncology Task Force, 2020–present
- SUS (Society of University Surgeons) Membership Committee, 2021–present

Editorial Boards:

- Associate Editor, *Journal of Surgical Oncology*, Surgical Technique Division, 2015–present
- Guest Editor, *Journal of Surgical Oncology*, Special Seminar Issue “Surgical Oncology Education”, 2019–2020
- ASO (Annals of Surgical Oncology) Editorial Board (Pancreas), 2020–present
- HPB (Hepatic-Pancreatico-Biliary) Editorial Board, 2021–present

Peter Hulick, MD

- American College of Medical Genetics and Genomics representative on the CancerLinQ Oncology Leadership Council for ASCO
- Epic Genetics and Genomics Steering Board Member
- Member, Personalized Medicine Coalition Public Policy Committee
- Member, Personalized Medicine Coalition Science Policy Committee
- Director on the American Board of Medical Genetics and Genomics

Karen Kaul, MD

- Trustee, American Board of Pathology
- Board Member, Clinical Laboratory 2.0
- Executive Committee and Chair of GME Committee, Association of Pathology Chairs
- Association for Molecular Pathology: Member, Covid response team, Curriculum Update team and Search Committee for new editor of *Journal of Molecular Diagnostics*

Janardan D. Khandekar, MD

Editorial:

- Associate Editor, *Journal of Surgical Oncology*, 2015–present

Katherine Kopkash, MD

- Program Chair, Chicago Surgical Society

Seth Krantz, MD

- Invited Question Writer, Self-Education Self-Assessment in Thoracic Surgery (SESATS 13), American Board of Thoracic Surgery
- Society of Thoracic Surgeons Workforce on Health Policy, Reform, and Advocacy, member

Editorial:

- Editorial Board: *Current Challenges in Thoracic Surgery*, 2019–present
- Reviewer: *Chest*, 2019–present, *Annals of Thoracic Surgery*, 2015–present, *Journal of Thoracic and Cardiovascular Surgery*, 2015–present

Robert Marsh, MD

- Eastern Cooperative Oncology Group, GI Committee

Editorial:

Reviewer: *American Journal of Clinical Oncology*, *British Medical Journal*, *Cancer*, *Cancer Management and Research*, *Cell*, *European Journal of Surgical Oncology*, *Journal of Cancer Research and Clinical Oncology*, *Journal of Surgical Oncology*, *Journal of the Pancreas*, *Lancet Oncology*, *Public Library of Science*, *Rogers Medical Intelligence Solutions CME Programs*, *Southern Medical Journal*, *Therapeutic Advances in Gastroenterology*

Awards:

Chicago Magazine Top Cancer Doctors, 2021

Leslie Mendoza Temple

Editorial:

- Guest Editor, *Complementary Therapies in Medicine*, Medical Cannabis Special Issue, 2020

Catherine E. Pesce, MD

- Society of Surgical Oncology—Breast Program Directors Subcommittee
- Early Careerist Award, NorthShore University HealthSystem Medical Group Award, 2020

Richard Prinz, MD

Editorial:

- Editorial Boards: *Surgery, Langenbeck's Archives of Surgery*
- Invited Reviewer: *American Journal of Surgery, Annals of Surgical Oncology, European Journal of Surgical Oncology, Gene Reports, Journal of the American College of Surgeons, Laryngoscope, Oral Oncology Radiation and Oncology, Surgical Oncology, Thyroid, World Journal of Surgery*

Joseph Raviv, MD

- Chicago Laryngological and Otolological Society—President Elect 2020-2021, President 2021–2022
- American Rhinologic Society (ARS)—Rhinology Training Council 2019–present

Presentations:

Wong A, Raviv J, Wong R. "Sellar Trough Trap Door Trans-Clival Reconstruction." North American Skull Base Society Annual Meeting. San Antonio, Texas. February, 2020.

Gustavo Rodriguez, MD

- Member, Cancer Prevention and Control Committee, Gynecologic Oncology Group/NRG, 1997–present
- Advisory Board, Gilda's Club, Chicago, 2004–present
- Medical Advisory Board, Chicago Ovarian Cancer Alliance, 2003–present

Awards:

- *Chicago Magazine* Top Cancer Doctors, Gynecologic Oncology, 2021

Carol Rosenberg, MD

- Mentor, Scholars in Oncology Associated Research Program (SOAR) at the University of Chicago, Pritzker School of Medicine covering multidisciplinary and interprofessional aspects of oncology (cancer) research and clinical care. NIH/NCI grant 1R25CA240134-01
- Key Informant—Johns Hopkins University Evidence-based Practice Center (EPC) and the Agency for Healthcare Research and Quality (AHRQ) Topic Refinement and Realist Reviewer on "Models of Pediatric-Adolescent-Adult Cancer Survivorship Care that include Primary Care"
- Research Investigator/Topic Reviewer: Women's Health Initiative Study, National Institutes of Health (NIH NHLBI)

Editorial:

- Reviewer: *ASCO Journal of Clinical Oncology (JCO) Oncology Practice*
- Reviewer: Oncology Section, American College of Physicians Medical Knowledge Self-Assessment Program (MKSAP 19)

Invited Presentations National:

- American College of Surgeons Quality and Safety Conference July 2021 virtual: Creating a Culture of Change in Survivorship. Presentation and Panelist: Building an Ecosystem of Survivorship Care: NorthShore's Living in the Future (MRW LIFE) Cancer Survivorship Program

Awards:

- Myra Rubenstein Weis LIFE Program Grant Award Recipient to the Myra Rubenstein Weis LIFE Cancer Survivorship program: Myra Rubenstein Weis Health Resource Center Foundation, Northshore University HealthSystem May, 2021

Daniel Shevrin, MD

- Community Co-Chair, ECOG GU Committee, 2005–present
- Medical Director, NorthShore Chapter of US TOO Prostate Cancer Support Group, 2002–present
- Director, Advocacy Core Prostate SPORE, Northwestern University, 2003–present
- Board Member, Cancer Wellness Center, Northbrook, IL, 2010–present

Awards:

- *Chicago Magazine* Top Cancer Doctors, 2021

Mark Sisco, MD, FACS

- Program Committee, Breast Subsection, American Society of Plastic Surgeons, 2015–present
- In-Service Examination Committee, American Society of Plastic Surgeons, 2016–present

Editorial:

- Editorial Board Member and Peer Reviewer, *Journal of Surgical Oncology*, 2014–present
- Peer Reviewer, *Journal of Surgical Research, Psycho-Oncology, Journal of Clinical Oncology and Microsurgery*

Smith, Norman

- Member, American Urological Association Relative Value Scale Update Committee (RUC), 2016–present; Coding and Reimbursement Committee, 2016–present; Public Policy Council, 2015–present
- Vice Chair, AMA/Specialty Society Relative Value Scale Update Committee (RUC) Relativity Assessment Workgroup (2019–present)
- Secretary/Treasurer and Executive Committee of Chicago Urologic Society

Mark Talamonti, MD

- PanCAN, Pancreatic Cancer Action Network, Ex Officio Member, Medical Advisory Committee
- American College of Surgeons Committee on Patient Safety and Improved Quality, High Risk GI Committee
- Americas Hepato-Pancreato-Biliary Association, 2018-2020; Finance Committee, 2019-2021; AHPBA Member at Large, Executive Council

Editorial:

- Editorial Board: *Annals of Surgical Oncology, Journal of Surgical Oncology*; Section Editor, *Hepatobiliary and Pancreas*

Elaine Wade, MD

Awards:

- *Chicago Magazine* Top Cancer Doctors, 2021

Lauren Wiebe, MD

- Palliative Care Research Cooperative Group, NorthShore Site Organizational Lead, 2017-present
- Palliative Care Research Cooperative Group (PCRC), Junior Investigator, 2014-present

Editorial:

- Invited Peer-Reviewer: *Journal of Palliative Medicine*, 2021

Awards:

- Coleman Foundation Grant: 4R Patient Care Sequences for Cancer and Supportive Care. Site Project Director for NorthShore University HealthSystem, 2019-2021
- PanCAN Patient Champion MD Award, 2021

David J Winchester, MD

- Director, Rice Foundation, 1998–present
- American Joint Committee on Cancer (AJCC), 2004–present; AJCC Education and Promotions Committee, 2007–present; AJCC Finance Committee, 2008–present; Vice Chairman, 2011–present; AJCC Executive Committee, 2011–present
- Member, Alliance ACS Clinical Research Program, 2012–present

Editorial:

- Member of Editorial Board, *American Journal of Clinical Oncology*, 2006–present; Associate Editor, 2009–present
- Member of Editorial Advisory Board, *American Family Physician*, 2012–present
- Member of Editorial Board, *Journal of Surgical Oncology*, 2015–present
- Ad Hoc Reviewer: *Annals of Surgical Oncology, British Journal of Cancer, Cancer, Canadian Medical Association Journal, Clinical Breast Cancer, Cancer Control: Journal Moffitt Cancer Center, Journal of Clinical Oncology, The Lancet Oncology, World Journal of Surgical Oncology*

Awards:

- *Chicago Magazine* Top Doctor 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021
- Americas Top Doctors for Cancer 2016, 2017, 2018, 2019, 2020

Katharine Yao, MD

- American Board of Surgery Certifying Exam Committee, Breast Section
 - Practice Advocacy Committee, American Society of Breast Surgeons
 - American College of Radiology, Supplemental Screening for Breast Density, Appropriateness Criteria Breast Imaging Committee
 - Prevention Committee of the Alliance, Women's Cancer Working Group Chair
 - Woman's Cancer Working Group Lead, Prevention Committee, Alliance for Clinical Trials
 - The COVID-19 Pandemic Breast Cancer Consortium
 - President, Chicago Surgical Society
 - Vice Chair, National Accreditation Program for Breast Centers
 - Member, Quality Integration Committee, Commission on Cancer
 - Western Surgical Association Executive Committee
- ### Editorial:
- Editorial Board: *Journal of Surgical Oncology, Annals of Surgical Oncology, Annals of Breast Surgery*

2021 Physician Directory



Matthew Adess, MD
Medical Director, Highland Park Kellogg Cancer Center
 Expertise: GI Oncology; Benign and Malignant Hematology
 Locations: GBK, GR, HPK



Allen Chen, MD
 Expertise: Interventional Radiology
 Locations: EH, GB, HP, SK



David Hahn, MD
 Expertise: Interventional Radiology
 Locations: EH, GB, HP, SK



Marc Alonzo, MD
 Expertise: Interventional Radiology
 Locations: EH, GB, HP, SK



Carolina Soto Chervin, MD
 Expertise: Lung Cancer; GI Oncology
 Locations: EVK, HPK



Britt Hanson, DO
 Expertise: Melanoma, Genitourinary Cancer, Benign and Malignant Hematology
 Locations: GR, HPK



Saad Arain, MD
 Expertise: Benign and Malignant Hematology
 Locations: GBK, HPK



Shakeel Chowdhry, MD
 Expertise: Surgery for Aneurysms; Endovascular Treatment for Aneurysms; Arteriovenous Malformations (AVMs); Interventional Stroke Therapy; Brain Tumors; Pituitary Tumors; Spinal Tumors
 Locations: EV, GB



Herbert Mason Hedberg, MD
 Expertise: Gastrointestinal & General Surgery
 Locations: EV, HP, SK



Hassan Arshad, MD
Director, Head and Neck Surgery
 Expertise: Head and Neck Cancer; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery
 Locations: EVK, NB, SW



Jeffrey Cilley, MD
Medical Director Swedish Hospital Cancer Center, President of Medical Staff, Swedish Covenant
 Expertise: Benign and Malignant Hematology; Medical Oncology
 Location: SW



Brian Helfand, MD, PhD
Division Head, Urology
 Expertise: Prostate Cancer
 Location: GB



Julian Bailes, MD
Chair, Department of Neurosurgery Co-Director, NorthShore Neurological Institute
 Expertise: Brain and Spine Tumor Surgery
 Locations: EV, HPS, SW



Peter Colegrove, MD
 Expertise: Urologic Oncology
 Locations: EV, GB



Thomas Hensing, MD, MS
Co-Director of the Thoracic Oncology Program, Associate Chief Quality Officer for Ambulatory Care
 Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancer
 Locations: EVK, GBK



William Bloomer, MD
Chair, Department of Radiation Oncology
 Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer
 Locations: EH, HPH



Allison DePersia, MD
 Expertise: High Risk Breast; Hereditary Cancer
 Location: EV



Melissa Hogg, MD, MS
Director, Liver and Pancreas Surgery
 Expertise: Gastrointestinal Surgical Oncology; Pancreatic Cancer; Primary and Metabolic Liver Tumors; Neuroendocrine Tumors; Sarcoma
 Locations: EVK, SW



Michael Blum, MD
 Expertise: Urologic Oncology
 Locations: EV, HPS



Thomas Farrell, MD
Section Head, Interventional Radiology
 Expertise: Interventional Radiology
 Locations: EH, GB, HP, SK



Peter Hulick, MD, MMSc
Division Head, Medical Genetics Director, Center for Personalized Medicine
 Expertise: Medical Genetics
 Location: EV



Bruce Brockstein, MD
Division Head, Hematology/Oncology, Medical Director, Kellogg Cancer Center; Kellogg-Scanlon Chair of Oncology
 Expertise: Head and Neck Cancers; Melanoma; Sarcoma
 Locations: EVK, HPK



Claus Fimmel, MD
 Expertise: Liver Diseases; Gastrointestinal Diseases; GI Endoscopy; Liver Biopsy
 Locations: EVK, HPS, SK



Javed Imam, MD
 Expertise: Benign and Malignant Hematology, Medical Oncology
 Location: SW



Elizabeth Burke, MD
 Expertise: Breast Reconstruction; Microsurgery; Melanoma; Facial Reconstructive Surgery
 Location: NMB



Alla Gimelfarb, MD
Medical Director, Kellogg Cancer Center Immediate Care
 Expertise: Benign and Malignant Hematology
 Location: GBK



Mary Tilley Jenkins Vogel, MD
 Expertise: Gynecologic Oncology
 Locations: EVK, GBK, SW



Nicholas Campbell, MD
 Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers
 Locations: EVK, HPK



David Grinblatt, MD
 Expertise: Benign and Malignant Hematology
 Locations: EVK, GBK



Lynne Kaminer, MD
Section Head, Hematology
 Expertise: Benign and Malignant Hematology
 Locations: EVK, GBK




Eileen Kelly, MD
 Expertise: Cardio-Oncology;
 Clinical Cardiology
 Location: GB



John Linn, MD
*Vice Chair for Surgery,
 Glenbrook Hospital*
 Expertise: Gastrointestinal Surgical
 Oncology Including Stomach and
 Esophagus; General Surgery
 Locations: EV, GBM



Ranjeev Nanda, MD
 Expertise: Stereotactic
 Radiosurgery; Brain Tumors;
 Head and Neck Cancers
 Locations: EH, GBH



Janardan Khandekar, MD
*Director, Center for Molecular
 Medicine*
 Expertise: Endocrine; Breast Cancer
 Location: EVK



Melissa Hachen Lippitt, MD, MPH
 Expertise: Gynecologic Oncology
 Locations: EVK, GBK



Kristian Novakovic, MD
 Expertise: Kidney Cancer; Prostate
 Cancer
 Locations: EV, GB



Carolyn Kirschner, MD
 Expertise: Gynecologic Oncology;
 Cancer Survivorship
 Locations: EVK, GBK



Luzheng Liu, MD
 Expertise: General Dermatology;
 Skin Cancers
 Location: LB



Bernhard Ortel, MD
 Expertise: Skin Cancer; General
 Dermatology; Psoriasis; Blistering
 Diseases
 Location: SKM



Madhuri Konanahalli, MD
 Expertise: Skin Cancer; General
 Dermatology
 Locations: EV, WM



Robert Marsh, MD
Section Head, GI Oncology
 Expertise: GI Oncology
 Locations: EVK, GBK



Sangtae Park, MD, MPH
 Expertise: Prostate Cancer;
 Urologic Oncology
 Locations: EV, GB



Katherine Kopkash, MD
*Director of Oncoplastic Breast
 Surgery*
 Expertise: Breast Cancer;
 Oncoplastic Breast Surgery; Breast
 Health; Breast Disease and Surgery
 Locations: EVB, GBB



Andrew Melnyk, MD
 Expertise: Medical Genetics
 Location: EV



Rupa Patil, MD
 Expertise: Cardio-Oncology;
 Clinical Cardiology
 Locations: EV, GB



Seth Krantz, MD
Chief, Division of Thoracic Surgery
 Expertise: Lung Cancer;
 Esophageal Cancer; Minimally
 Invasive Thoracic Surgery
 Locations: EVK, HPK



Gregg Menaker, MD
 Expertise: Mohs Surgery;
 Dermatologic Surgery; Laser Surgery
 Location: SKM



Catherine Pesce, MD
Division Head, Surgical Oncology
 Expertise: Breast Cancer; Breast
 Health; Breast Disease and Surgery
 Location: HP



Monika Krezalek, MD
 Expertise: Minimally Invasive
 Colon and Rectal Surgery; Colon
 and Rectal Cancer; Inflammatory
 Bowel Disease; Anorectal Surgery;
 Colonoscopy
 Locations: EV, GB, HPS



Douglas Merkel, MD
 Expertise: Breast Cancer
 Locations: EVK, GBK, HPK



Nicklas Pfanzerler, MD
 Expertise: Genitourinary Cancer,
 Lung Cancer, Melanoma
 Locations: EVK, GBK, HPK



Elyse Lambiase, MD
 Expertise: Benign and Malignant
 Hematology; Medical Oncology
 Location: SW



Tricia Moo-Young, MD
 Expertise: Minimally Invasive
 Approaches to Endocrine Disorders;
 Thyroid and Parathyroid Surgery;
 Adrenal Disorders; Cancer and
 Disease Management
 Locations: HPS, VH



Ariel Polish, MD
 Expertise: GI Oncology; Benign
 and Malignant Hematology;
 Genitourinary Cancer; Lung
 Cancer
 Locations: EVK, GBK, GR



Teresa Murray Law, MD
 Expertise: Breast Cancer
 Locations: EVK, HPK



Elena Moore, MD
 Expertise: Gynecologic Oncology
 Locations: EVK, HPK



Richard Prinz, MD
*Vice Chair, Administration & Clinical
 Development, Department of Surgery*
 Expertise: Endocrine Surgery; Thyroid,
 Parathyroid, and Pancreatic Surgery
 and Management; Biliary and General
 Surgery
 Locations: HPS, MP, SK



Ross Levy, MD
 Expertise: Mohs Surgery;
 Dermatologic Surgery; Laser Surgery
 Location: SKM



Joseph Muldoon, MD
 Expertise: Minimally Invasive Colon
 and Rectal Cancer; Inflammatory Bowel
 Disease; General Surgery
 Locations: EV, GB



Amit Pursnani, MD
 Expertise: Cardio-Oncology;
 Clinical Cardiology
 Location: SK

continued >



Vathsala Raghavan, MD
 Expertise: Breast Cancer;
 Gynecologic Oncology;
 Head and Neck Cancers;
 Thyroid Cancer
 Locations: GBH, HPH



Arif Shaikh, MD
 Expertise: Stereotactic Radiosurgery;
 Head and Neck Cancers; Lung
 Cancer; Gynecologic and Breast
 Tumors
 Locations: EH, GBH



Leslie Mendoza Temple, MD
Medical Director, Integrative Medicine
 Expertise: Integrative Medicine
 Location: GP



Joseph Raviv, MD
Division Head, Otolaryngology
 Expertise: Nasal and Sinus Surgery;
 Endoscopic Skull Base Surgery
 Locations: NB, SK



Daniel Shevrin, MD
*Medical Director,
 Glenbrook Kellogg Cancer Center*
 Expertise: Prostate Cancer;
 Genitourinary Cancer
 Locations: EVK, GBK



Michael Ujiki, MD
*Division Head, Gastrointestinal
 & General Surgery*
 Expertise: Gastrointestinal Surgical
 Oncology Including Stomach and
 Esophagus; Minimally Invasive
 Endoscopic Surgery; General Surgery
 Locations: EV, GBM



Sidney Regalado, MD
 Expertise: Interventional Radiology
 Locations: EH, GB, HP, SK



Mark Sisco, MD
*Division Head, Plastic and
 Reconstructive Surgery*
 Expertise: Plastic Surgery;
 Breast Reconstruction
 Location: NMB



Elaine Lee Wade, MD
 Expertise: Breast Cancer
 Location: GBK



Erwin Robin, MD
 Expertise: Benign and Malignant
 Hematology
 Locations: GBK, HPK



Norm Smith, MD
 Expertise: Bladder Cancer;
 Testicular Cancer; Kidney Cancer;
 Advanced Urologic Cancers
 Locations: EV, GB



Jason Waldinger, MD
Interim Division Head, Dermatology
 Expertise: Skin Cancer; General
 Dermatology; Laser Procedures
 Location: LB



Jason Robin, MD
 Expertise: Cardio-Oncology;
 Clinical Cardiology
 Location: GB



Alan Smookler, MD
 Expertise: Internal Medicine,
 Palliative Medicine
 Location: GBK



Amy Wang, MD
 Expertise: Benign and Malignant
 Hematology
 Location: EVK



Gustavo Rodriguez, MD
*Division Head,
 Gynecologic Oncology*
 Expertise: Gynecologic Oncology
 Locations: EVK



James Spitz, MD
 Expertise: Colon and Rectal Surgery;
 Colonoscopy; General Surgery
 Locations: GBM, HP, VH



Lauren Wiebe, MD
 Expertise: Internal Medicine;
 Palliative Medicine; GI Oncology
 Locations: EVK, GBK



Carol Rosenberg, MD
*Director, Preventive Health Initiatives;
 Director, Myra Rubenstein Weis
 Living in the Future (LIFE) Cancer
 Survivorship Program*
 Expertise: Cancer Survivorship
 Location: HPH



Katherine Wailen Su, MD
 Expertise: Esophageal Cancer; Lung
 Cancer; Mediastinal Tumors; Benign
 Esophageal Disease; Paraesophageal;
 Minimally Invasive Thoracic Surgery;
 Advanced Endoscopy/Bronchoscopy
 Locations: EVK, HPK



David J. Winchester, MD
*Associate Medical Director for Surgical
 Services, Kellogg Cancer Center
 NorthShore University HealthSystem*
 Expertise: Surgical Oncology with
 Emphasis on Breast, Endocrine,
 Melanoma and Sarcoma
 Locations: GBB, GBM, SK



Poornima Saha, MD
 Expertise: Breast Cancer
 Locations: EVK, GBK



Auddie Sweis, MD
 Expertise: Nasal and Sinus
 Surgery; Endoscopic Skull Base
 Surgery; General Otolaryngology
 Locations: LB, SW



Ricky Wong, MD
 Expertise: Deep Brain and Vagal
 Nerve Stimulators; Brain and Skull
 Base Tumors; Pituitary Tumor;
 Cerebral Aneurysms; Arterio-Venous
 Malformation (AVM); Trigeminal
 Neuralgia
 Locations: EV, GB



Akhil Seth, MD
 Expertise: Breast Reconstruction;
 Aesthetic Breast and Body Surgery;
 Oncologic and Complex Wound
 Reconstruction
 Location: NMB



Mark Talamonti, MD
Department Chair, Surgery
 Expertise: Gastrointestinal Surgical
 Oncology; Pancreatic Cancer;
 Benign and Malignant Liver Tumors;
 Neuroendocrine Tumors
 Location: EVK



Katharine Yao, MD
*Vice Chair, Research and Development
 Department of Surgery*
 Expertise: Breast Cancer; Breast
 Health; Breast Disease and Surgery
 Locations: EVB, GBB

Locations

Evanston Breast Center (EVB)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Hospital (EH)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Kellogg Cancer Center (EVK)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Specialty Suites (EV)

1000 Central Street, Evanston, IL 60201

Glenbrook Breast Center (GBB)

2050 Pfingsten Road, Suite 130
Glenview, IL 60026

Glenbrook Hospital (GBH)

2100 Pfingsten Road, Glenview, IL 60026

Glenbrook John and Carol Walter Ambulatory Care Center (GB)

2180 Pfingsten Road, Glenview, IL 60026

Glenbrook Kellogg Cancer Center (GBK)

2180 Pfingsten Road, Suite 1000
Glenview, IL 60026

Glenbrook Medical Building (GBM)

2050 Pfingsten Road, Suite 128
Glenview, IL 60026

Glenview Park Center (GP)

2400 Chestnut Avenue, Glenview, IL 60026

Gurnee Ambulatory Care Center (GR)

7900 Rollins Road, Gurnee, IL 60031

Highland Park Ambulatory Care Center (HPS)

757 Park Avenue West
Highland Park, IL 60035

Highland Park Breast Center (HPB)

777 Park Avenue West, Suite B400
Highland Park, IL 60035

Highland Park Hospital (HPH)

777 Park Avenue West, Room 1260
Highland Park, IL 60035

Highland Park Kellogg Cancer Center (HPK)—Ellen Marks Ambulatory Care Center

757 Park Avenue West, Suite 1810
Highland Park, IL 60035

Highland Park Medical Building (HP)

767 Park Avenue West, Suite B100
Highland Park, IL 60035

Lake Bluff Medical Building (LB)

71 Waukegan Road, Suite 700
Lake Bluff, IL 60044

Mount Prospect Medical Building (MP)

1329 Wolf Road, Mount Prospect, IL 60056

Northbrook Medical Building (NMB)

501 Skokie Boulevard
Northbrook, IL 60062

NorthShore Medical Group (SKM)—Skokie

9933 Woods Drive, Suite 200
Skokie, IL 60077

Northwest Community Healthcare

800 West Central Road
Arlington Heights, IL 60005

Skokie Ambulatory Care Center (SK)

9650 Gross Point Road, Suite 3000
Skokie, IL 60076

Swedish Hospital (SW)

5140 N. California Avenue
Chicago, IL 60625

Vernon Hills Specialty Suites (VH)

225 North Milwaukee Avenue
Vernon Hills, IL 60061

Wilmette Medical Office (WM)

1515 Sheridan Road, Suite 31A
Wilmette, Illinois 60091

Cancer Conferences

Breast Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Mondays, 7:30 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Colorectal Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868
2nd and 4th Fridays, 7 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Genitourinary Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Fridays, 7 a.m.
NorthShore Glenbrook Hospital Videocast

Gynecology Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Thursdays, 7 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Head and Neck Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Thursdays, 8 a.m.

Hematology/Pathology Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, 8 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Hepatic Biliary Pancreatic Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, 7 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Molecular Oncology Conferences

NorthShore Evanston Hospital
Kellogg Room 4818, 1st Friday, 7 a.m.

Neuro-Oncology Cancer Conferences


NorthShore Evanston Hospital
Kellogg Room G868
2nd and 4th Wednesdays, 7:30 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Sarcoma/Melanoma Conferences

NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Wednesdays, 8 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Thoracic Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, noon
NorthShore Glenbrook and Highland Park
Hospitals Videocast



Evanston Hospital
2650 Ridge Avenue
Evanston, Illinois 60201
(847) 570-2000

Glenbrook Hospital
2100 Pflingsten Road
Glenview, Illinois 60026
(847) 657-5800

Highland Park Hospital
777 Park Avenue West
Highland Park, Illinois 60035
(847) 432-8000

**Northwest Community
Healthcare/Hospital**
800 West Central Road
Arlington Heights, IL 60005
(847) 618-1000

Skokie Hospital
9600 Gross Point Road
Skokie, Illinois 60076
(847) 677-9600

Swedish Hospital
5140 N. California Avenue
Chicago, IL 60625
(773) 878-8200

Medical Group
1301 Central Street
Evanston, Illinois 60201
(847) 570-5235

Foundation
1033 University Place, Suite 450
Evanston, Illinois 60201
(224) 364-7200

Research Institute
1001 University Place
Evanston, Illinois 60201
(224) 364-7100



1301 Central Street
Evanston, Illinois 60201

northshore.org

2021 Cancer Committee

Chairman

David J. Winchester, MD, FACS
Associate Director for Surgical Specialties,
Kellogg Cancer Center
NorthShore Cancer Committee Chairman
Board of Directors, David P. Winchester, MD,
Chair of Surgical Oncology

Physician Membership*

Matthew Adess, MD
Medical Director, Highland Park
Kellogg Cancer Center

Bruce Brockstein, MD
Medical Director, Kellogg Cancer Center,
Kellogg-Scanlon Chair of Oncology

David Grinblatt, MD
Director, Oncology Research Program
Head, Division of Hematology/Oncology,
Kellogg Cancer Center

Thomas Hensing, MD, MS
Co-Director, Thoracic Oncology Program
Head of Quality, Kellogg Cancer Center
Deputy Division Head,
Division of Hematology and Oncology
Medical Director, Evanston Kellogg Cancer
Center
NorthShore Cancer Committee Quality
Improvement Coordinator

Monika Krezalek, MD
GI Surgery

Elena Moore, MD
Gynecologic Oncology

Cancer Liaison Physician

Seth Krantz, MD
Thoracic Oncology

Kristian Novakovic, MD
Urologic Oncology

James Padgett, MD
Pathology

Ajit Paintal, MD
Pathology

Catherine Pesce, MD
Surgical Oncology

Nick Pfanzer, MD
Clinical Research Coordinator

Vathsala Raghavan, MD
Radiation Oncology

Carol Rosenberg, MD
Director, Myra Rubenstein Weis
Living in the Future (LIFE) Cancer
Survivorship Program
Survivorship Program Coordinator

Poornima Saha, MD
Medical Oncology

Georgia Spear, MD
Diagnostic Radiology

Lauren Wiebe, MD
Palliative Care

Ancillary Membership

Jonella Black, PT, MS
Program Coordinator,
Rehab Services

Kim Cholewa, BSN
Oncology Nursing

Jamie Feld, RN
Cancer Committee Coordinator
Cancer Registry

Linda Green, RN, MS, AOCNS
Director, Medical Group Operations,
Oncology Nursing
Kellogg Cancer Center

Sharon Huginnie
Senior Applications Analyst I
Epic IP/HOV Team
Health Information Technology
NorthShore University HealthSystem

Rachel Mees
Assistant Vice President,
Medical Group
Cancer Program Administrator
Kellogg Cancer Center

Moha Mehta
Assistant Vice President,
Integrated Marketing and
Corporate Communications

Sabina Omercajic, MS, CCRP
Outreach Coordinator
Kellogg Cancer Center

Anna Palafox
Senior Director, Oncology Pharmacy

Anisha Patel, APN
Clinical Coordinator,
Living in the Future (LIFE)
Cancer Survivorship Program

Shayna Purcell, MS, CGC
Medical Genetics

Denise Rehberger, RN, BSN
Manager, Hospice

Jessica Smith
Cancer Control Strategic
Partnerships Manager
American Cancer Society Liaison

Irene Ziaya, LCSW
Psychosocial Services
Coordinator/Social Work

Debra Ziegler, MLIS, CTR
Quality Coordinator, Cancer Registry
NorthShore Cancer Committee
Cancer Registry Quality Coordinator
Cancer Conference Coordinator

Lisa Zoberman, RDN, LDN
Oncology Nutrition
Kellogg Cancer Center

* All academic affiliations are with the University of Chicago Pritzker School of Medicine